Tivity Health (TVTY) 10-K 2 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Feb. 19, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	TIVITY HEALTH, INC.
Entity Central Index Key	0000704415
Current Fiscal Year End Date	--12-31
Trading Symbol	TVTY
Title of 12(b) Security	Common Stock - $.001 par value
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 487.1
Entity Common Stock, Shares Outstanding		49,151,491
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-19364
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	62-1117144
Entity Address, Address Line One	701 Cool Springs Boulevard
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	800
Local Phone Number	869-5311
ICFR Auditor Attestation Flag	true
Documents Incorporated by Reference	Portions of the registrant's Proxy Statement for the 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K.

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents		$ 100,385	$ 2,486
Accounts receivable, net		25,981	84,194
Prepaid expenses		5,556	7,740
Income taxes receivable		10,996	4,978
Other current assets		11,336	7,155
Current assets of discontinued operation			60,162
Total current assets		154,254	166,715
Property and equipment, net of accumulated depreciation of $38,188 and $32,532 respectively		20,959	23,576
Right-of-use assets		18,139	25,575
Long-term deferred tax asset		3,601
Intangible assets, net		29,049	29,049
Goodwill, net		334,680	334,680
Other assets		18,301	22,992
Long-term assets of discontinued operation			1,028,296
Total assets		578,983	1,630,883
Current liabilities:
Accounts payable		19,741	28,099
Accrued salaries and benefits		8,949	6,886
Accrued liabilities		18,424	37,640
Deferred revenue		4,460	4,336
Current portion of long-term debt	[1]	7,456
Current portion of lease liabilities		8,052	7,898
Current portion of other long-term liabilities		14,753	4,947
Current liabilities of discontinued operation			64,740
Total current liabilities		81,835	154,546
Long-term debt		459,250	1,048,127
Long-term lease liabilities		11,494	19,585
Long-term deferred tax liability			4,222
Other long-term liabilities		22,748	11,292
Long-term liabilities of discontinued operation			169,411
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock $.001 par value, 5,000,000 shares authorized, none outstanding
Common Stock $.001 par value, 120,000,000 shares authorized, 48,983,735 and 48,156,786 shares outstanding, respectively		49	48
Additional paid-in capital		513,263	504,419
Accumulated deficit		(464,085)	(240,494)
Treasury stock, at cost, 2,254,953 shares in treasury		(28,182)	(28,182)
Accumulated other comprehensive loss		(17,389)	(12,091)
Total stockholders' equity		3,656	223,700
Total liabilities and stockholders' equity		$ 578,983	$ 1,630,883
[1]	Represents additional term loan principal due upon final settlement of the sale of Nutrisystem based on the estimated post-Closing adjustments.

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Accumulated depreciation	$ 38,188	$ 32,532
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares outstanding (in shares)	48,983,735	48,156,786
Treasury stock (in shares)	2,254,953	2,254,953

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenues		$ 437,714	$ 633,066	$ 606,299
Cost of revenue (exclusive of depreciation of $9,209, $5,920, and $4,109, respectively, included below)		250,362	445,817	418,333
Marketing expense		12,197	17,720	14,417
Selling, general and administrative expenses		42,991	53,198	35,077
Depreciation expense		9,930	7,137	4,667
Restructuring and related charges		4,358	1,881	124
Operating income		117,876	107,313	133,681
Interest expense		43,477	41,803	8,733
Income before income taxes		74,399	65,510	124,948
Income tax expense		17,530	20,293	27,046
Income from continuing operations		56,869	45,217	97,902
Income (loss) from discontinued operations, net of income tax (benefit) of ($46,851), ($59,881) and $325, respectively		(280,500)	(332,038)	901
Net income (loss)		$ (223,631)	$ (286,821)	$ 98,803
Earnings (loss) per share - basic:
Continuing operations		$ 1.17	$ 0.97	$ 2.44
Discontinued operations		(5.75)	(7.14)	0.02
Net income (loss)	[1]	(4.59)	(6.17)	2.47
Earnings (loss) per share – diluted:
Continuing operations		1.16	0.96	2.27
Discontinued operations		(5.70)	(7.05)	0.02
Net income (loss)		$ (4.54)	$ (6.09)	$ 2.29
Comprehensive income (loss)		$ (228,929)	$ (298,912)	$ 98,803
Weighted average common shares and equivalents:
Basic		48,746	46,509	40,078
Diluted		49,217	47,103	43,073
[1]	Figures may not add due to rounding.

CONSOLIDATED STATEMENTS OF OP_2

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Depreciation	$ 9,209	$ 5,920	$ 4,109
Discontinued operation, income tax (benefit)	$ (46,851)	$ (59,881)	$ 325

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ (223,631)	$ (286,821)
Net change in fair value of effective portion of interest rate swaps designated as cash flow hedges, net of tax benefit of $5,540 and $4,147, respectively	(16,151)	(12,091)
Reclassification adjustment for loss from interest rate swaps de- designated as cash flow hedges included in "Income (loss) from discontinued operations, net," net of tax of $3,661	10,675
Reclassification adjustment for previously deferred loss from interest rate swaps included in "Interest expense," net of tax of $61	178
Total other comprehensive loss, net of tax	(5,298)	(12,091)
Comprehensive income (loss)	$ (228,929)	$ (298,912)

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net change in fair value of effective portion of interest rate swaps designated as cash flow hedges, tax benefit	$ 5,540	$ 4,147
Reclassification adjustment for loss from interest rate swaps de-designated as cash flow hedges, tax	3,661
Reclassification adjustment for previously deferred loss from interest rate swaps, tax	$ 61

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Treasury Stock	Accumulated Other Comprehensive Income (Loss)
Balance at Dec. 31, 2017	$ 268,743	$ 40	$ 349,243	$ (52,358)	$ (28,182)
Comprehensive income	98,803			98,803
Exercise of stock options and Warrants	1,910	1	1,909
Tax withholding for share-based compensation	(9,762)		(9,762)
Share-based employee compensation expense	6,097		6,097
Balance at Dec. 31, 2018	365,791	41	347,487	46,445	(28,182)
Comprehensive income	(298,912)			(286,821)		$ (12,091)
Issuance of Common Stock in connection with Merger	132,838	6	132,832
Share-based compensation Replacement Awards related to Merger and attributable to pre-combination services	9,107		9,107
Exercise of stock options	989	1	988
Tax withholding for share-based compensation	(4,733)		(4,733)
Share-based employee compensation expense	18,832		18,832
Other	(212)		(94)	(118)
Balance at Dec. 31, 2019	$ 223,700	48	504,419	(240,494)	(28,182)	(12,091)
Common stock shares beginning at Dec. 31, 2019	48,156,786
Comprehensive income	$ (228,929)			(223,631)		(5,298)
Exercise of stock options	1,025	1	1,024
Tax withholding for share-based compensation	(6,257)		(6,257)
Share-based employee compensation expense	14,077		14,077
Other	40			40
Balance at Dec. 31, 2020	$ 3,656	$ 49	$ 513,263	$ (464,085)	$ (28,182)	$ (17,389)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Income from continuing operations	$ 56,869	$ 45,217	$ 97,902
Income (loss) from discontinued operations, net of income tax (benefit) of ($46,851), ($59,881) and $325, respectively	(280,500)	(332,038)	901
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	45,887	50,775	4,667
Amortization and write-off of deferred loan costs	9,190	4,487	1,152
Amortization and write-off of debt discount	8,604	3,711	4,140
Share-based employee compensation expense	14,077	18,832	6,097
Loss on derivatives	14,544
Impairment of goodwill and intangible assets of discontinued operation	199,500	377,100
Loss (gain) on sale of business	90,163		(1,304)
Deferred income taxes	(38,438)	(52,076)	25,485
Decrease (increase) in accounts receivable, net	63,239	(8,283)	(12,311)
Decrease in other current assets	1,129	1,661	1,610
Decrease in accounts payable	(3,182)	(10,052)	(95)
Increase (decrease) in accrued salaries and benefits	128	3,608	(10,314)
Decrease in other current liabilities	(19,152)	(21,495)	(11,802)
Increase (decrease) in deferred revenue	686	(1,198)
Other	6,703	2,056	2,611
Net cash flows provided by operating activities	169,447	82,305	108,739
Cash flows from investing activities:
Acquisition of property and equipment	(15,525)	(24,713)	(9,053)
Proceeds from sale of business, net of cash transferred	558,067		1,416
Settlement on derivatives not designated as hedges	(1,499)
Business acquisitions, net of cash acquired		(1,062,818)
Net cash flows provided by (used in) investing activities	541,043	(1,087,531)	(7,637)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	196,525	1,611,970	253,425
Payments of long-term debt	(795,100)	(574,329)	(373,536)
Proceeds from settlement of cash convertible notes hedges			141,246
Payments related to settlement of cash conversion derivative			(141,246)
Payments related to tax withholding for share-based compensation	(6,257)	(4,733)	(9,762)
Exercise of stock options	1,025	989	1,910
Deferred loan costs		(30,189)
Change in cash overdraft and other	(8,784)	2,083	410
Net cash flows provided by (used in) financing activities	(612,591)	1,005,791	(127,553)
Effect of exchange rate changes on cash		(12)	(56)
Net increase (decrease) in cash and cash equivalents	97,899	553	(26,507)
Cash and cash equivalents, beginning of period	2,486	1,933	28,440
Cash and cash equivalents, end of period	100,385	2,486	1,933
Supplemental disclosure of cash flow information:
Cash paid for interest	71,439	67,717	4,099
Cash paid for income taxes, net of refunds	20,433	$ 8,370	$ 3,339
Nutrisystem
Noncash investing activities:
Net working capital settlement expected from sale of Nutrisystem (see Note 2)	$ 2,844

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Tivity Health, Inc. (the “Company”) was founded and incorporated in Delaware in 1981. Through our four programs, SilverSneakers ® ® TM TM becoming the modern destination for healthy living, especially for seniors and older adults Beginning in February 2020, the Board of Directors engaged in a comprehensive review of the Company’s long-term strategy, including reviewing the Company’s core capabilities and ability to best deliver increased shareholder value through actions that would improve our balance sheet and best focus management on the creation of value. On May 6, 2020, we announced that our Board had commenced a process to explore strategic alternatives with respect to the Nutrition business, including a possible transaction. On October 18, 2020, we entered into a Stock Purchase Agreement (“Purchase Agreement”) with Kainos NS Holdings LP, a Delaware limited partnership (“Parent”), and KNS Acquisition Corp., a Delaware corporation and indirect wholly owned subsidiary of Parent (“Purchaser,” and collectively with Parent, “Kainos”) to sell to Kainos all of the issued and outstanding capital stock of Nutrisystem, Inc. (“Nutrisystem”), a wholly owned subsidiary of the Company that included the Nutrisystem ® ® results of operations for Nutrisystem have been classified as discontinued operations for all periods presented in the accompanying consolidated financial statements, and all related assets and liabilities have been classified as discontinued operations at December 31, 2019. Effective as of December 9, 2020, we completed the sale of Nutrisystem to Kainos pursuant to the terms of the Purchase Agreement. At the closing (the “Closing”) of the transactions contemplated by the Purchase Agreement, Nutrisystem and its subsidiaries were acquired by, and became wholly owned subsidiaries of, Kainos. Our results from continuing operations also do not include the results of MeYou Health, LLC (“MeYou Health”), which we sold in June 2016. Results of operations for MeYou Health have been classified as discontinued operations for all periods presented in the accompanying consolidated financial statements. Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In our opinion, the accompanying consolidated financial statements of Tivity Health, Inc. and its wholly owned subsidiaries (collectively, “Tivity Health,” the “Company,” or such terms as “we,” “us,” or “our”) reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement. We have reclassified certain items in prior periods to conform to current classifications. In addition, we have recorded a correction to deferred revenue as of January 1, 2018, the earliest date presented in the consolidated financial statements, to reflect additional performance obligations that were unsatisfied at such time. Such adjustment resulted in a $3.2 million increase to deferred revenue, with a related decrease to retained earnings as of January 1, 2018. We concluded that this adjustment was not material to any prior annual or interim period. a. Principles of Consolidation – See discussion above regarding Nutrisystem and MeYou Health. We have eliminated all intercompany profits, transactions, and balances. b. Cash and Cash Equivalents - Cash and cash equivalents primarily include cash on deposit. c. Accounts Receivable, net - Accounts receivable includes billed and unbilled amounts. Billed receivables represent fees that are contractually due for services performed or products sold, net of allowances for doubtful accounts (reflected as selling, general and administrative expenses). Allowances for doubtful accounts were $0 at December 31, 2020 and 2019, respectively. Historically, we have experienced minimal instances of customer non-payment and therefore consider our accounts receivable to be collectible; however, we provide reserves, when appropriate, for doubtful accounts on a specific identification basis. Unbilled receivables were $5.7 million and $29.1 million at December 31, 2020 and 2019, respectively, and d. Property and Equipment - Property and equipment is carried at cost and includes expenditures that increase value or extend useful lives. We recognize depreciation using the straight-line method over useful lives of three to seven years for computer software and hardware and four to seven years for furniture and office equipment, and three to five years for equipment. Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the life of the lease, which ranges from two to fifteen years. Depreciation expense, including depreciation of assets recorded under finance leases, for the years ended December 31, 2020, 2019, and 2018 was $9.9 million, $7.1 million, and $4.7 million, respectively. e. Other Assets - Other assets consist primarily of 159,309 shares of common stock of Sharecare, Inc. which have a carrying value of $10.8 million and are accounted for as a cost method investment, and customer incentives. We have elected the measurement alternative to measure cost method investments that do not have a readily determinable fair value at cost less impairment, adjusted by observable price changes, with any fair value changes recognized in earnings. f. Leases – On January 1, 2019, we adopted Accounting Standards Update (“ASU”) No. 2016-02 using the modified retrospective approach. We recognize right-of-use assets and lease liabilities for leases with contractual terms longer than twelve months, and we categorize such leases as either operating or finance. Finance leases are generally those leases that allow us to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. Our leases generally have remaining lease terms of one to 45 months, some of which include options to extend the lease for additional periods. Such extension options were not considered in the value of the asset or liability since it is not probable that we will exercise the options to extend. If applicable, allocations among lease and non-lease components would be achieved using relative fair values. Lease liabilities are recognized at the present value of the fixed lease payments, reduced by landlord incentives using a discount rate based on similarly secured borrowings available to us. Lease assets are recognized based on the initial present value of the fixed lease payments, reduced by landlord incentives, plus any direct costs from executing the leases. Leasehold improvements are capitalized at cost and amortized over the lesser of their expected useful life or the lease term. Costs associated with right-of-use assets are recognized on a straight-line basis within operating expenses over the term of the lease. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest method over the lease term. See Note 9 for further information on leases. g. Intangible Assets - Intangible assets subject to amortization include acquired technology and distributor and provider networks, which we amortized on a straight-line basis over estimated useful lives ranging from three to ten years. All intangible assets related to continuing operations and subject to amortization were fully amortized at December 31, 2020 and 2019. We assess the potential impairment of intangible assets subject to amortization whenever events or changes in circumstances indicate that the carrying values may not be recoverable. If we determine that the carrying value of other identifiable intangible assets may not be recoverable, we calculate any impairment using an estimate of the asset's fair value based on the estimated price that would be received to sell the asset in an orderly transaction between market participants. Intangible assets related to continuing operations and not subject to amortization at December 31, 2020 and 2019 consist of a trade name of $29.0 million. We review indefinite-lived intangible assets for impairment on an annual basis (during the fourth quarter of our fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable. We estimate the fair value of our indefinite-lived tradename using the relief-from-royalty method, which requires us to estimate significant assumptions such as the long-term growth rates of future revenues associated with the tradename, the royalty rate for such revenue, the terminal growth rate of revenue, the tax rate, and a discount rate. Changes in these estimates and assumptions could materially affect the estimate of fair value for the tradename. See Note 6 for further information on intangible assets. h. Goodwill - We recognize goodwill for the excess of the purchase price over the fair value of tangible and identifiable intangible net assets of businesses that we acquire. We review o mp e o e e i e o e o e t n i d i u u en t n e n that th carryin v lu ma no b r e cov e rab l e single As part of the annual impairment test o e m n i o a n w i i o a n i l During a quantitative review of goodwill, we estimate the fair value of the reporting unit based on a discounted cash flow model or a combination of a discounted cash flow model and market-based approaches, and we reconcile the fair value of the reporting unit to our consolidated market capitalization. If the fair value of the reporting unit exceeds its carrying amount, no impairment is indicated. If the fair value of the reporting unit is less than its carrying amount, impairment of goodwill is measured as the excess of the carrying amount over fair value. Estimating fair value requires significant judgments, including management's estimate of future cash flows of each reporting unit (which is dependent on internal forecasts of projected income), estimation of the long-term growth rates of future revenues for our reporting units, the terminal growth rate of revenue, the tax rate, and determination of our weighted average cost of capital, as well as relevant comparable company revenue and earnings multiples and market participant acquisition premium for the market-based fair value and potential goodwill impairment for each reporting unit i. Accounts Payable - Accounts payable consists of short-term trade obligations and includes cash overdrafts attributable to disbursements not yet cleared by the bank. j. Accrued Liabilities – Accrued liabilities primarily include amounts owed for estimated member visits to fitness network locations (which actual visit data is typically received approximately one month in arrears k. Income Taxes - We file a consolidated federal income tax return that includes all of our wholly owned subsidiaries. U.S. GAAP generally requires that we record deferred income taxes for the tax effect of differences between the book and tax bases of our assets and liabilities. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are expected to be realized. When we determine that it is more likely than not that we will be able to realize our deferred tax assets in the future, an adjustment to the deferred tax asset is made and reflected in income. l. Revenue Recognition - On January 1, 2018, we adopted ASU No. 2014-09 using the modified retrospective transition method applied to contracts that were not completed as of January 1, 2018. See Note 4 for a further discussion of revenue recognition. m. Marketing Expense – Marketing expense includes media, advertising production, marketing, and promotional expenses and payroll-related expenses, including share-based payment arrangements, for personnel engaged in these activities. Media expense from continuing operations was $7.2 million, $7.1 million, and $1.0 million in 2020, 2019, and 2018, respectively. Internet advertising expense is recorded based on either the rate of delivery of a guaranteed number of impressions over the advertising contract term or on a cost per customer acquired, depending upon the terms. All other advertising costs are charged to expense as incurred or, in the case of production costs, the first time the advertising takes place. At December 31, 2020 and 2019, $0 million and $1.7 million, respectively, of costs have been prepaid for future advertisements and promotions within continuing operations. n. Earnings (Loss) Per Share – Beginning in 2019, we use the two-class method to calculate earnings per share (“EPS”) as the unvested restricted stock awards outstanding under our equity incentive plan were participating shares with nonforfeitable rights to dividends. Under the two-class method, we compute earnings per share of common stock by dividing the sum of distributed earnings to common stockholders (not applicable as we do not pay dividends) and undistributed earnings allocated to common stockholders by the weighted average number of outstanding shares of common stock for the period. In applying the two-class method, we allocate undistributed earnings to both shares of common stock and participating securities based on the number of weighted average shares outstanding during the period. During periods of net loss, no effect is given to the participating securities because they do not share in the losses of the Company. See o. Share-Based Compensation – We recognize all share-based payments to employees in the consolidated statements of operations over the required vesting period based on estimated fair values at the date of grant. See Note 7 for a further discussion of share-based compensation. p. Derivative Instruments and Hedging Activities – We generally use derivative instruments to add stability to interest expense and to manage our exposure to interest rate movements. We account for derivatives in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 815, which establishes accounting and reporting standards requiring that certain derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivative’s fair value will be recognized currently in earnings unless specific hedge accounting criteria are met. For derivatives that are designated and qualify as effective cash flow hedges, the unrealized gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive income (loss) and reclassified into earnings as interest expense when the hedged transaction affects earnings. If a derivative instrument ceases to be a highly effective hedge, we will discontinue hedge accounting prospectively for the affected derivative instrument. The application of the authoritative guidance could impact the volatility of earnings. See Note 13 for further information on derivative instruments and hedging activities. q. Management Estimates – In preparing our consolidated financial statements in conformity with U.S. GAAP, management must make estimates and assumptions that affect: (1) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and (2) the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2020
Discontinued Operations And Disposal Groups [Abstract]
Discontinued Operations	2. Effective as of December 9, 2020, we completed the sale of Nutrisystem to Kainos for We estimate such working capital adjustment will result in additional proceeds to be received in 2021 of $2.8 million, which we have recorded in other current assets at December 31, 2020. Additionally, we incurred $11.2 million of transaction costs directly related to the disposition of Nutrisystem, resulting in estimated net proceeds, after post-Closing adjustment, of $550.5 million. In accordance with ASC Topic 205, “Presentation of Financial Statements”, the Nutrition business met the criteria for discontinued operations at December 31, 2020, as it was a component of the Company and the sale represented a strategic shift in the Company’s operations and financial results. Accordingly, the results of operations of the Nutrition business have been classified as discontinued operations for 2019 and 2020, and the assets and liabilities as of December 31, 2019 have been reclassified to discontinued operations. The following table presents the aggregate carrying amounts of the major classes of assets and liabilities related to the disposition of the Nutrition business: (In thousands) December 31, 2019 Accounts receivable, net $ 13,402 Inventories 36,150 Prepaid expenses 10,515 Other current assets 95 Current assets of discontinued operation 60,162 Property and equipment, net 29,333 Right-of-use assets 17,624 Intangible assets, net 660,637 Goodwill, net 319,956 Other assets 746 Long-term assets of discontinued operation 1,028,296 Total assets of discontinued operation $ 1,088,458 Accounts payable $ 18,381 Accrued salaries and benefits 6,184 Accrued liabilities 18,024 Deferred revenue 10,911 Income taxes payable 5,383 Current portion of lease liabilities 5,857 Current liabilities of discontinued operation 64,740 Long-term lease liabilities 11,816 Long-term deferred tax liability 156,624 Other long-term liabilities 971 Long-term liabilities of discontinued operation 169,411 Total liabilities of discontinued operation $ 234,151 The following table presents financial results of the Nutrition business included in “income (loss) from discontinued operations" for the years ended December 31, 2020 and 2019. Results of operations for the year ended December 31, 2018 for the Nutrition business are not included as the Company did not acquire the Nutrition business until March 8, 2019, and there is no impact of the sale on the year ended December 31, 2018. Year Ended December 31 (In thousands) 2020 (1) 2019 (2) Revenues $ 617,191 $ 498,091 Cost of revenues 291,097 232,240 Marketing expenses 196,952 140,286 Selling, general and administrative expenses 59,093 56,840 Depreciation and amortization 35,957 43,638 Impairment loss 199,500 377,100 Restructuring and related charges 472 5,143 Interest expense (3) 36,798 34,763 Pretax loss from discontinued operations (202,678 ) (391,919 ) Loss on de-designation of cash flow hedges (4) (14,336 ) — Write-off of deferred loan costs and debt discount (3) (8,946 ) — Loss on sale of Nutrition business (5) (101,391 ) — Total pretax loss on discontinued operations $ (327,351 ) $ (391,919 ) Income tax benefit (46,851 ) (59,881 ) Loss from discontinued operations, net of income tax benefit $ (280,500 ) $ (332,038 ) (1) Results include the period from January 1, 2020 through December 8, 2020. (2) Results include the period from March 8, 2019 (the date of acquisition) through December 31, 2019. (3) The term loans under our Credit Agreement were originated with the purchase of Nutrisystem on March 8, 2019. Following the disposition of Nutrisystem, we repaid $519.0 million of principal on the Term Loans under the terms of the Credit Agreement. In conjunction with the partial debt prepayment, we wrote off a portion of the related deferred loan costs and original issue discount. We allocated interest expense to discontinued operations based on the interest expense incurred from March 8, 2019 through December 8, 2020 related to $519.0 million of term loan debt, using our historical interest rates. (4) Represents loss recognized in the fourth quarter of 2020 in connection with the de-designation of cash flow hedging on interest rate swaps (see Note 13). (5) Consists of impairment losses of $90.2 million related to Nutrisystem goodwill (see Note 12), which includes post-Closing adjustments related to final settlement, and $11.2 million of transaction costs directly related to the disposition of Nutrisystem. The depreciation, amortization and significant operating and investing non-cash items of the discontinued operations were as follows: Year Ended December 31 (In thousands) 2020 2019 Impairment of goodwill and intangible assets $ 199,500 $ 377,100 Loss on sale of business 90,163 — Depreciation and amortization 35,957 43,638 Loss on de-designation of cash flow hedges 14,336 — Write-off of deferred loan costs and debt discount (1) 8,946 — Capital expenditures on discontinued operations 6,794 10,168 Share-based compensation on discontinued operations 4,351 13,230 Deferred income taxes (54,561 ) (68,488 ) (1) Reflected on the consolidated statement of cash flows in the line items “Amortization and write-off of deferred loan costs” and “Amortization and write-off of debt discount”.

Recent Relevant Accounting Stan

Recent Relevant Accounting Standards	12 Months Ended
	Dec. 31, 2020
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recent Relevant Accounting Standards	3 . Re c o a d In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, “ Reference Rate Reform (“ASC 848”): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”. ASC 848 contains temporary optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform, such as a transition away from the use of LIBOR. ASC 848 was effective for the Company as of January 1, 2020. The provisions of ASC 848 are available through December 31, 2022, at which time the reference rate replacement activity is expected to have been completed. The provisions of ASC 848 must be applied at a Topic, Subtopic or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. The accounting relief provided by ASC 848 is applicable only to legacy contracts if the amendments made to the agreements are solely for reference rate reform activities. Modifications that are unrelated to reference rate reform will scope out a given contract. ASC 848 allows for different elections to be made at different points in time, and the timing of those elections will be documented as applicable. For the avoidance of doubt, we intend to reassess the elections of optional expedients and exceptions included within ASC 848 related to our hedging activities and will document the election of these items on a quarterly basis. In March 2020, we elected the expedient that allows us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform. In addition, we have the option to change the method of assessing effectiveness upon a change in the critical terms of the derivative or the hedged transactions and upon the end of relief under ASC 848. In June 2020, we elected to (i) continue the method of assessing effectiveness as documented in the original hedge documentation and (ii) apply the expedient wherein the reference rate on the hypothetical derivative matches the reference rate on the hedging instrument. We will also apply the aforementioned elections to any future designated cash flow hedging relationship. In October 2018, the FASB issued ASU 2018-16, "Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (“SOFR”) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes" (“ASU 2018-16”), which adds the OIS rate based on SOFR as a U.S. benchmark interest rate to facilitate the LIBOR to SOFR transition and provide lead time for entities to prepare for changes to interest rate risk hedging strategies. ASU 2018-16 is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. As of December 31, 2020, the benchmark interest rate in our existing interest rate swap agreements is LIBOR. The adoption of this standard did not have an impact on our financial position, results of operations, or cash flows . In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”), which changes the fair value measurement disclosure requirements of ASC 820. ASU 2018-13 is effective for fiscal years beginning on or after December 15, 2019, including interim periods therein, and is generally required to be applied retrospectively, except for certain components that are to be applied prospectively. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures In August 2018, the FASB issued ASU No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract,” which requires implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement, if those costs would be capitalized by the customer in a software licensing arrangement. This standard is effective for annual periods beginning after December 15, 2019, and interim periods within those fiscal years. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires companies to measure credit losses for financial assets held at the reporting date utilizing a methodology that reflects current expected credit losses over the lifetime of such assets. ASU 2016-13 was effective for the Company on January 1, 2020 and is generally required to be applied using the modified retrospective approach, with limited exceptions for specific instruments. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Revenue Recognition	4. Revenue Recognition Beginning in 2018, we account for revenue from contracts with customers in accordance with ASC Topic 606. The unit of account in ASC Topic 606 is a performance obligation, which is a promise in a contract to transfer to a customer either a distinct good or service (or bundle of goods or services) or a series of distinct goods or services provided over a period of time. ASC Topic 606 requires that a contract's transaction price, which is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, is to be allocated to each performance obligation in the contract based on relative standalone selling prices and recognized as revenue when or as the performance obligation is satisfied. We earn revenue from continuing operations primarily from three programs: SilverSneakers senior fitness, Prime Fitness, and WholeHealth Living. We provide the SilverSneakers senior fitness program to members of Medicare Advantage, Medicare Supplement, and group retiree plans through our contracts with such plans. We offer Prime Fitness, a fitness facility access program, through contracts with commercial health plans, employers, and other sponsoring organizations that allow their members to individually purchase the program. We sell our WholeHealth Living program primarily to health plans. Except for Prime Fitness, our customer contracts generally have initial terms of approximately three years. Some contracts allow the customer to terminate early and/or determine on an annual basis to which of their members they will offer our programs. For Prime Fitness, our contracts with commercial health plans, employers, and other sponsoring organizations generally have initial terms of approximately three years, while i . The significant majority of customer contracts contain one Deferred revenue was $4.5 million and $4.3 million at December 31, 2020 and 2019, respectively. During 2020, we recognized $3.6 million of revenue that was included in deferred revenue at December 31, 2019 and increased deferred revenue by $3.8 million, excluding amounts recognized as revenue during 2020. Our fees are variable month to month and are generally billed per member per month (“PMPM”) or billed based on a combination of PMPM and member visits to a network location. We bill PMPM fees by multiplying the contractually negotiated PMPM rate by the number of members eligible for or receiving our services during the month. T he average monthly total participation levels of our members were significantly lower in fiscal year 2020 than in 2019 due to the COVID-19 pandemic. As a result, revenues from PMPM fees represented 54% of SilverSneakers revenue for the year ended December 31, 2020, compared to 33% for the year ended December 31, 2019. December 31, 20 20 and 2019 , amortization expense related to such capitalized costs w as $0.4 million and $0.1 million , respectively . No such capitalized costs were amortized during the year ended December 31, 2018. Our customer contracts include variable consideration, which is allocated to each distinct month over the contract term based on eligible members and/or member visits each month. The allocated consideration corresponds directly with the value to our customers of our services completed for the month. Under the majority of contracts, we recognize revenue each month using the practical expedient available under ASC 606-10-55-18, which provides that revenue is recognized in the amount for which we have the right to invoice. ASC 606-10-50-14(b) provides an optional exemption, which we have elected to apply, from disclosing remaining performance obligations when revenue is recognized from the satisfaction of the performance obligation in accordance with the “right to invoice” practical expedient. Although we evaluate our financial performance and make resource allocation decisions based upon the results of our single The following table sets forth revenue from continuing operations disaggregated by program. Revenue from our SilverSneakers program is predominantly contracted with Medicare Advantage and Medicare Supplement plans. (In thousands) Year Ended December 31 2020 2019 2018 SilverSneakers $ 313,575 $ 492,778 $ 487,559 Prime Fitness 95,015 120,949 101,391 WholeHealth Living 19,776 18,511 16,835 Other (1) 9,348 828 514 $ 437,714 $ 633,066 $ 606,299 (1) For the year ended December 31, 2020, other revenue in the table above includes $6.8 million from a well-being program with a large employer (which we do not expect to recur at this level) and $2.2 million from our Wisely Well program. Sales and usage-based taxes are excluded from revenues.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Property and Equipment	5 . Property and Equipment Property and equipment at December 31, 2020 and 2019 consisted of the following: (In thousands) December 31, 2020 December 31, 2019 Leasehold improvements $ 7,963 $ 7,659 Computer equipment and related software 45,504 30,256 Furniture and office equipment 4,418 6,173 Capital projects in process 1,262 12,020 Total property and equipment at cost $ 59,147 $ 56,108 Less: accumulated depreciation (38,188 ) (32,532 ) Total property and equipment, net $ 20,959 $ 23,576

Intangible Assets and Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	6 . Intangible Assets and Goo d w i ll There was no c h g the m d of continuing operations i r n e b 31 2020 or 2019. Intangible assets subject to amortization at December 31, 2020 and 2019 consisted of the following: (In thousands) Gross Carrying Amount Accumulated Amortization Net Acquired technology $ 1,483 $ (1,483 ) — Distributor and provider networks 8,709 (8,709 ) — Total $ 10,192 $ (10,192 ) $ — As all intangible assets subject to amortization were fully amortized as of December 31, 2016, no amortization was incurred during the years ended December 31, 2020, 2019, and 2018, and no amortization expense is expected over the next five years and thereafter. At December 31, 2020 and 2019, intangible assets not subject to amortization consisted of a tradename of

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	7 . Share-Based Compensation We currently have h e a e d a d oc n performance-based stock units, and market stock units h ba a a d a e o l e e o o c l We grant options under our stock incentive plan at fair value on the date of grant. The options generally vest over or at the end of three years based on service conditions and expire seven or ten years from the date of grant. Restricted stock units generally vest over three or four years. Performance-based stock units have a multi-year performance period and vest approximately two or three years from the grant date. Market stock units granted during 2020 have a three-year In March 2019, we granted the following awards related to our assumption of unvested restricted stock awards and performance stock units, respectively, held by Nutrisystem employees (“Replacement Awards”): (i) approximately 258,000 time-vesting restricted stock awards at a fair value of $19.42 per share and (ii) approximately 919,000 time-vesting restricted stock units at a fair value of $19.42 per share. We recognize share-based compensation expense for options, restricted stock units, performance-based stock units, and restricted stock awards on a straight-line basis over the vesting period. We account for forfeitures as they occur. We recognize share-based compensation expense for market stock units if the requisite service period is rendered, even if the market condition is never satisfied. All awards generally provide for accelerated vesting upon a change in control or normal or early retirement (as defined in the applicable equity award agreement or stock incentive plan). In the fourth quarter of 2020, the compensation committee of the Company’s Board of Directors approved the acceleration of certain unvested stock-based compensation awards in connection with the sale of Nutrisystem. At December 31, 2020, we had reserved approximately 1.4 million shares for future equity grants under our stock incentive plans. Following are certain amounts recognized in the consolidated statements of operations for share-based compensation arrangements for the years ended December 31, 2020, 2019, and 2018. We did not capitalize any share-based compensation costs during these periods. Year Ended December December December 31, (In millions) 2020 2019 2018 Share-based compensation included in cost of revenue $ 2.7 $ 2.2 $ 2.3 Share-based compensation included in selling, general and administrative expenses 6.2 3.4 3.8 Share-based compensation included in restructuring and related charges 0.8 — — Share-based compensation included in continuing operations $ 9.7 $ 5.6 $ 6.1 Share-based compensation included in discontinued operations 4.4 13.2 — Total share-based compensation $ 14.1 $ 18.8 $ 6.1 Total income tax benefit recognized in continuing operations 2.5 1.4 1.6 As of December 31, 2020, there was $14.2 million of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under our stock incentive plan. That total cost is expected to be recognized over a weighted average period of 1.6 years. Stock Options We use a lattice-based binomial option valuation model ("lattice binomial model") to estimate the fair values of stock options. We base expected volatility on historical volatility due to the low volume of traded options on our stock. The expected term of options granted is derived from the output of the lattice binomial model and represents the period of time that options granted are expected to be outstanding. We used historical data to estimate expected option exercise and post-vesting employment termination behavior within the lattice binomial model. The following table sets forth the weighted average grant-date fair values of options and the weighted average assumptions we used to develop the fair value estimates for the years ended December 31, 2020 and 2018. There were no stock options granted during fiscal 2019. Year Ended December 2020 Year Ended December 2019 Year Ended December 2018 Weighted average grant-date fair value of options per share $ 8.20 $ — $ 20.21 Assumptions: Expected volatility 63.2 % — 56.2 % Expected dividends — — — Expected term (in years) 6.2 — 6.7 Risk-free rate 0.7 % — 2.8 % A summary of options as of December 31, 2020 and the activity during the year then ended is presented below: Options Shares (In Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding at January 1, 2020 319 $ 17.85 Granted 220 16.78 Exercised (81 ) 12.67 Forfeited (5 ) 39.55 Expired (31 ) 20.76 Outstanding at December 31, 2020 422 $ 17.83 5.2 $ 1,544 Exercisable at December 31, 2020 187 $ 17.54 3.0 $ 927 The total intrinsic value, which represents the difference between the market price of the underlying common stock and the option's exercise price, of options exercised during the years ended December 31, 2020, 2019, and 2018 was $0.6 million, $0.6 million, and $3.9 million, respectively. Cash received from option exercises under all share-based payment arrangements during 2020 was $1.0 million. The actual tax benefit realized during 2020 for the tax deductions from option exercise totaled $0.2 million. We issue new shares of common stock upon exercise of stock options or vesting of restricted stock units, restricted stock awards, performance-based stock units, and market stock units. Nonvested Shares The fair value of restricted stock units and performance-based stock units is determined based on the closing bid price of the Company's common stock on the grant date. The weighted average grant-date fair value of restricted stock units granted during the years ended December 31, 2020, 2019, and 2018 was $11.17, $19.68, and $38.12, respectively. The weighted average grant-date fair value of performance-based stock units granted during the years ended December 31, 2020 and 2019 was $21.49 and $20.20, respectively. No performance-based stock units were granted during 2018. The Monte Carlo simulation valuation model is used to determine the fair value of market stock units. The weighted average grant-date fair value of all market stock units granted during 2020 was $18.84. No market stock units were granted during 2019 or 2018. The four tables below set forth a summary of our nonvested shares as of December 31, 2020 as well as activity during the year then ended, including the acceleration of certain shares in connection with the divestiture of Nutrisystem. The total grant-date fair value of shares vested during the years ended December 31, 2020, 2019, and 2018 was $13.6 million, $23.5 million, and $7.6 million, respectively. The following table shows a summary of our restricted stock awards as of December 31, 2020, as well as activity during the year then ended: Restricted Stock Awards Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2020 127 $ 19.42 Vested (120 ) 19.42 Forfeited (7 ) 19.42 Nonvested at December 31, 2020 — $ — The following table shows a summary of our restricted stock units as of December 31, 2020 as well as activity during the year then ended: Restricted Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2020 393 $ 21.16 Granted 1,774 11.17 Vested (692 ) 13.81 Forfeited (234 ) 17.96 Nonvested at December 31, 2020 1,241 $ 11.58 The following table shows a summary of our performance-based stock units as of December 31, 2020, as well as activity during the year then ended: Performance Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2020 407 $ 20.29 Granted 4 21.49 Shares adjustment for performance (1) (74 ) 20.26 Vested (86 ) 20.42 Forfeited (165 ) 20.26 Nonvested at December 31, 2020 86 $ 20.30 (1) Represents the number of shares at target for certain performance-based stock units that are no longer eligible to be earned as a result of actual performance being below the applicable performance targets. These awards are included in the nonvested balance at January 1, 2020 and the number of shares granted above. The following table shows a summary of our market stock units as of December 31, 2020 as well as activity during the year then ended: Market Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2020 — $ — Granted 150 18.84 Nonvested at December 31, 2020 150 $ 18.84

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	8 . Income Taxes Income tax expense is comprised of the following: Year Ended December 31, (In thousands) 2020 2019 2018 Current taxes: Federal $ 526 $ 3,051 $ 29 State 881 830 1,857 Deferred taxes: Federal 14,114 11,853 20,136 State 2,009 4,559 5,024 Total $ 17,530 $ 20,293 $ 27,046 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table sets forth the significant components of our net deferred tax asset and liability as of December 31, 2020 and 2019: (In thousands) December 31, 2020 December 31, 2019 Deferred tax asset: Accruals and reserves $ 1,137 $ 498 Deferred compensation 604 191 Share-based payments 2,909 2,802 Lease liability 4,993 5,003 Section 163(j) interest limitation 370 5,647 Interest rate swap 5,964 4,147 Unrealized losses 3,720 — Net operating loss carryforwards 10,608 7,200 Capital loss carryforwards 149,608 7,801 179,913 33,289 Valuation allowance (152,295 ) (13,147 ) $ 27,618 $ 20,142 Deferred tax liability: Property and equipment $ (4,516 ) $ (3,181 ) Intangible assets (14,868 ) (14,651 ) Right-of-use assets (4,633 ) (6,532 ) (24,017 ) (24,364 ) Net long-term deferred tax asset (liability) $ 3,601 $ (4,222 ) At December 31, 2020, we provided valuation allowances for $2.4 million of deferred tax assets associated with our international net operating loss carryforwards, $0.3 million of deferred tax assets associated with our state net operating loss carryforwards, and $149.6 million for deferred tax assets related to capital loss carryforwards generated in the sale of the total population health services business in 2016 and the sale of Nutrisystem in 2020. Capital loss carryforwards can only be used to offset future capital gains and cannot be used to offset any future operating losses the Company may incur. We recorded a total increase in our valuation allowance of $139.1 million for the year ended December 31, 2020. Our valuation allowance at December 31, 2019 totaled $13.1 million. At December 31, 2020, we had international net operating loss carryforwards totaling approximately $8.2 million, $8.0 million of which have an indefinite carryforward period, approximately $159.0 million of state net operating loss carryforwards expiring between 2021 and 2036, and approximately $598.4 million of capital loss carryforwards expiring between 2021 and 2025. We recorded a tax effect of $6.0 million in 2020 related to our interest rate swap agreements to stockholder’s equity as a component of accumulated other comprehensive income (loss). The difference between income tax expense computed using the statutory federal income tax rate and the effective rate is as follows: Year Ended December 31, (In thousands) 2020 2019 2018 Statutory federal income tax $ 15,624 $ 13,757 $ 26,239 State income taxes, less federal income tax benefit 3,607 3,048 6,261 Permanent items 1,131 306 1,496 Change in valuation allowance (2,659 ) 2,509 (1,005 ) Share-based compensation 426 210 (6,378 ) State income tax credits — 954 677 Change in uncertain tax position liability — — (644 ) Prior year tax adjustments (592 ) (464 ) (590 ) Net impact of foreign operations 3 (9 ) 990 Other (10 ) (18 ) — Income tax expense $ 17,530 $ 20,293 $ 27,046 Uncertain Tax Positions During 2020, we recorded a $1.1 million decrease to unrecognized tax benefits primarily related to the unrecognized tax benefits divested in the sale of Nutrisystem. As of December 31, 2020, we had no unrecognized tax benefits that would affect our effective tax rate. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. The aggregate changes in the balance of unrecognized tax benefits, exclusive of interest, were as follows: (In thousands) Unrecognized tax benefits at December 31, 2018 $ — Increases related to acquisition of Nutrisystem 1,006 Increases related to current year tax positions 8 Increases related to prior year tax positions 66 Decreases due to lapse of statute of limitations (19 ) Unrecognized tax benefits at December 31, 2019 $ 1,061 Increases related to prior year tax positions 84 Decreases due to lapse of statute of limitations (20 ) Decreases related to Nutrisystem divestiture (1,125 ) Unrecognized tax benefits at December 31, 2020 $ — We file income tax returns in the U.S. Federal jurisdiction and in various state and foreign jurisdictions. Tax years remaining subject to examination in the U.S. Federal jurisdiction include 2017 to present.

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Leases	9 . Leases On January 1, 2019, we adopted ASC 842 using the modified retrospective approach. Therefore, the comparative information for periods ended prior to January 1, 2019 was not restated. With the exception of two finance leases related to a network server and office equipment, all of our leases are classified as operating leases. We maintain lease agreements principally for our office spaces and certain equipment. We maintain two sublease agreements with respect to one of our office locations, each of which continues through the initial term of our master lease agreement. Such sublease income and payments, while they reduce our rent expense, are not considered in the value of the right-of-use asset or lease liability. In the aggregate, our leases generally have remaining lease terms of one to 45 months, some of which include options to extend the lease for additional periods. Such extension options were not considered in the value of the right-of-use asset or lease liability because it is not probable that we will exercise the options to extend. If applicable, allocations among lease and non-lease components would be achieved using relative standalone selling prices. Upon adoption of ASC 842, we determined our estimated discount rate for existing leases as of January 1, 2019 based on the incremental borrowing rate that most closely aligned with the remaining lease term and payment schedule, as provided by our financial institution. The discount rates for leases entered into after January 1, 2019 were determined based on similarly secured borrowings available to us as of lease inception. The following table shows the right-of-use assets and lease liabilities recorded on the balance sheet: December 31, 2020 December 31, 2019 (In thousands) Right-of-use assets: Operating $ 17,145 $ 23,895 Finance 994 1,680 Total leased assets $ 18,139 $ 25,575 Lease liabilities: Current Operating $ 7,408 $ 7,274 Finance 644 624 Non-current Operating $ 11,097 $ 18,505 Finance 397 1,080 Total lease liabilities $ 19,546 $ 27,483 The following table shows the components of lease expense: Year Ended December 31, Year Ended December 31, (In thousands) 2020 2019 Finance lease cost: Amortization of leased assets $ 686 $ 298 Interest of lease liabilities 86 51 Operating lease cost 7,872 8,817 Total lease cost before subleases $ 8,644 $ 9,166 Sublease income (5,452 ) (5,479 ) Total lease cost, net $ 3,192 $ 3,687 The following provides information related to the lease term and discount rate as of December 31, 2020: Weighted Average Remaining Lease Term (years) Operating leases 2.6 Finance leases 1.6 Weighted Average Discount Rate Operating leases 4.8 % Finance leases 5.9 % As of December 31 aturities of lease liabilities for each of the next five years and thereafter were as follows: Operating Leases Financing (In thousands) Lease Payments Sublease Receipts Net Leases 2021 8,115 (5,699 ) 2,416 686 2022 7,957 (5,732 ) 2,225 403 2023 2,518 (957 ) 1,561 — 2024 1,083 — 1,083 — Total lease payments 19,673 $ (12,388 ) $ 7,285 1,089 Less: interest (1,168 ) (48 ) Present value of lease liabilities $ 18,505 $ 1,041 Supplemental cash flow information related to leases was as follows: Year Ended December 31, Year Ended December 31, (In thousands) 2020 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flow attributable to operating leases $ (3,492 ) $ (4,626 ) Operating cash flow attributable to finance leases (86 ) (51 ) Financing cash flow attributable to finance leases (622 ) (274 ) Supplemental noncash information: Right-of-use assets obtained in exchange for operating lease liabilities (1) — 31,538 Right-of-use assets obtained in exchange for finance lease liabilities (2) — 1,978 (1) No new operating leases were entered into during the year ended December 31, 2019. Amount shown is due to the adoption of ASC 842 and one lease modification that resulted in a noncash remeasurement of the related right-of-use asset and operating lease liability. Amount shown reflects balance as of January 1, 2019, adjusted for lease modification. (2) Amount shown is due to the adoption of ASC 842 and one new finance lease for $1.8 million entered into during the year ended December 31, 2019. In addition to such lease, amount shown reflects balance as of January 1, 2019.

Debt

Debt	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt	10 . Debt The Company's debt, net of unamortized deferred loan costs and original issue discount, consisted of the following at December 31, 2020 and 2019: (In thousands) December 31, 2020 December 31, 2019 Term Loan A $ 124,035 $ 288,750 Term Loan B 372,240 786,250 Revolving credit facility — 19,850 496,275 1,094,850 Less: deferred loan costs and original issue discount (29,569 ) (46,723 ) Total debt 466,706 1,048,127 Less: current portion (1) (7,456 ) — Total long-term debt $ 459,250 $ 1,048,127 (1) Represents additional term loan principal due upon final settlement of the sale of Nutrisystem based on the estimated post-Closing adjustments. Credit Facility In connection with the consummation of our merger with Nutrisystem (the “Merger”), on March 8, 2019, we entered into a new Credit and Guaranty Agreement (the “Credit Agreement”) with a group of lenders, Credit Suisse AG, Cayman Islands Branch, (“Credit Suisse”), as general administrative agent, term facility agent and collateral agent, and SunTrust Bank, (“SunTrust”), as revolving facility agent and swing line lender. The Credit Agreement provides us with (i) a $350.0 million term loan A facility (“Term Loan A”), (ii) an $830.0 million term loan B facility (“Term Loan B” and, together with Term Loan A, the “Term Loans”), (iii) a $125.0 million revolving credit facility that includes a $35.0 million sublimit for swingline loans and a $50.0 million sublimit for letters of credit (the “Revolving Credit Facility”; Term Loan A, Term Loan B and the Revolving Credit Facility are sometimes herein referred to collectively as the “Credit Facilities”), and (iv) uncommitted incremental accordion facilities in an aggregate amount at any date equal to the greater of $125.0 million or 50% of our consolidated EBITDA for the then-preceding four fiscal quarters, plus additional amounts based on, among other things, satisfaction of certain financial ratio requirements. As of December 31, 2020, outstanding debt under the Credit Agreement was $ 466.7 million, and availability under the Revolving Credit Facility totaled $ 124.5 million as calculated under the most restrictive covenant . We are required to repay Term Loan A loans in consecutive quarterly installments, each in the amount of 2.50% of the aggregate initial amount of such loans, payable on June 30, 2019 and on the last day of each succeeding quarter thereafter until maturity on March 8, 2024, at which time the entire outstanding principal balance of such loans is due and payable in full. We are required to repay Term Loan B loans in consecutive quarterly installments, each in the amount of 0.75% of the aggregate initial amount of such loans, payable on June 30, 2019 and on the last day of each succeeding quarter thereafter until maturity on March 8, 2026, at which time the entire outstanding principal balance of such loans is due and payable in full. We are permitted to make voluntary prepayments of borrowings under the Term Loans at any time without penalty. From March 8, 2019 through December 31 We are required to repay in full any outstanding swingline loans and revolving loans under the Revolving Credit Facility on March 8, 2024. In addition, the Credit Agreement contains provisions that, beginning with fiscal 2019, may require annual excess cash flow (as defined in the Credit Agreement and generally designed to equal cash generated by our business in excess of cash used in the business) to be applied towards the Term Loans. We are required to make prepayments on the Term Loans equal to our excess cash flow for a given fiscal year multiplied by the following excess cash flow percentages based on our Net Leverage Ratio (as defined in the Credit Agreement) on the last day of such fiscal year: (a) 75% if the Net Leverage Ratio is greater than 3.75:1, (b) 50% if the Net Leverage Ratio is equal to or less than 3.75:1 but greater than 3.25:1 (c) 25% if the Net Leverage Ratio is equal to or less than 3.25:1 but greater than 2.75:1, and (d) 0% if the Net Leverage Ratio is equal to or less than 2.75:1. Any such potential mandatory prepayments are reduced by voluntary prepayments. We were not required to make an Excess Cash Flow Payment for fiscal 2020. The Credit Agreement contains a financial covenant that requires us to maintain maximum ratios or levels of consolidated total net debt to consolidated adjusted EBITDA, calculated as provided in the Credit Agreement (the “Net Leverage Ratio”), of 5.75:1.00 for all test dates occurring on or after December 31, 2019 but prior to December 31, 2020, 5.25:1.00 for all test dates occurring on or after December 31, 2020 but prior to December 31, 2021, and 4.75:1.00 for all test dates occurring on or after December 31, 2021. As of December 31, 2020, we were in compliance with all of the covenant requirements of the Credit Agreement, and our Net Leverage Ratio was equal to 2.36. Based on our current assumptions with respect to the COVID-19 pandemic, including, among other things, the outstanding principal on the term loans under our Credit Agreement following the repayment of $519 million in December 2020, our fitness partner locations reopening and/or remaining open, and the average monthly total participation levels of our members at such locations, we currently believe we will be in compliance with the Net Leverage Ratio covenant over the next 12 months. We will continue to monitor our projected ability to comply with all covenants under the Credit Agreement, including the Net Leverage Ratio. Borrowings under the Credit Agreement bear interest at variable rates based on a margin or spread in excess of either (1) one-month, two-month, three-month or six-month LIBOR (or, with the approval of all lenders holding the particular class of loans, 12-month LIBOR), which may not be less than zero, or (2) the greatest of (a) the prime lending rate of the agent bank for the particular facility, (b) the federal funds rate plus 0.50%, and (c) one-month LIBOR plus 1.00% (the “Base Rate”), as selected by the Company. The LIBOR margin for Term Loan A loans is 4.25%, the LIBOR margin for Term Loan B loans is 5.25% and the LIBOR margin for revolving loans varies between 3.75% and 4.25%, depending on our total Net Leverage Ratio Net Leverage Ratio Under these agreements, we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest equal to approximately 2.2 % plus a spread, as described in the preceding sentences. As further explained in Note 13, during the fourth quarter of 2020 we concluded that five of the eight interest rate swaps no longer qualified for hedge accounting treatment, and we de-designated these derivatives. As of December 31, 20 20 , the eight interest rate swap agreements had current notional amounts totaling $ million , of which $ 388.9 million relate d to effective hedges . For the year ended December 31, 2020, the effective interest rates related to continuing operations for Term Loan A and Term Loan B (exclusive of payments related to de-designated interest rate swaps, which we do not classify as interest expense) were 6.64 % and 7.08 %, respectively. For the year ended December 31, 2019, the effective interest rates related to continuing operations for Term Loan A and Term Loan B were % and %, respectively. The Credit Agreement also provides for annual commitment fees ranging between 0.250% and 0.500% of the unused commitments under the Revolving Credit Facility, depending on our total Net Leverage Ratio, and annual letter of credit fees on the daily outstanding availability under outstanding letters of credit at the applicable LIBOR margin for the Revolving Credit Facility, depending on our total Net Leverage Ratio. During the each of the years ended December 31, 2020 and 2019, we incurred total such commitment fees of $0.5 million. Extensions of credit under the Credit Agreement are secured by guarantees from substantially all of the Company’s active material domestic subsidiaries and by security interests in substantially all of the Company’s and such subsidiaries’ assets. The Credit Agreement also contains various other affirmative and negative covenants customary for financings of this type that, subject to certain exceptions, impose restrictions and limitations on us and certain of our subsidiaries with respect to, among other things, indebtedness; liens; negative pledges; restricted payments (including dividends, distributions, buybacks, redemptions, repurchases with respect to equity interests, and payments, redemptions, retirements, purchases, acquisitions, defeasance, exchange, conversion, cancellation or termination with respect to junior lien, subordinated or unsecured debt); restrictions on subsidiary distributions; loans, advances, guarantees, acquisitions and other investments; mergers and other fundamental changes; sales and other dispositions of assets (including equity interests in subsidiaries); sale/leaseback transactions; transactions with affiliates; conduct of business; amendments and waivers of organizational documents and material junior debt agreements; and changes to fiscal year. The following table summarizes the minimum annual principal payments and repayments of the revolving advances under the Credit Agreement for each of the next five years and thereafter: (In thousands) Year ending December 31, 2021 $ 7,456 (1) 2022 59,900 2023 59,900 2024 77,071 2025 24,900 2026 and thereafter 267,048 Total $ 496,275 (1) The total term loan principal due during 2021 reflects $7.5 million of additional debt repayment required upon estimated final settlement of the Nutrisystem sale.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11 . Commitments and Contingencies Shareholder Lawsuits: Weiner Lawsuit and Consolidated Derivative Lawsuit On November 6, 2017, United Healthcare issued a press release announcing expansion of its fitness benefits (“United Press Release”), and the market price of the Company's shares of common stock, par value $0.001 per share (“Common Stock”) dropped on that same day. In connection with the United Press Release , four lawsuits were filed against the Company. Of the four lawsuits, one has been dismissed, two were dismissed and after plaintiffs appealed, now have a final settlement pending court approval, and one remains actively contested. We are currently not able to predict the probable outcome of the remaining matter or to reasonably estimate a range of potential loss, if any. We intend to vigorously defend ourselves against the remaining complaint. On November 20, 2017, Eric Weiner, claiming to be a stockholder of the Company, filed a complaint on behalf of stockholders who purchased Common Stock between February 24, 2017 and November 3, 2017 (“Weiner Lawsuit”). The Weiner Lawsuit was filed as a class action in the U.S. District Court for the Middle District of Tennessee, naming as defendants the Company, the Company's chief executive officer, chief financial officer and a former executive who served as both chief accounting officer and interim chief financial officer. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10b-5 promulgated under the Exchange Act in making false and misleading statements and omissions related to the United Press Release. The complaint seeks monetary damages on behalf of the purported class. On April 3, 2018, the Court entered an order appointing the Oklahoma Firefighters Pension and Retirement System as lead plaintiff, designated counsel for the lead plaintiff, and established certain deadlines for the case. On June 4, 2018, plaintiff filed a first amended complaint. . On January 26, 2018 and August 24, 2018, individuals claiming to be stockholders of the Company filed shareholder derivative actions, on behalf of the Company, in the U.S. District Court for the Middle District of Tennessee, naming the Company as a nominal defendant and certain current and former executives and directors as defendants. On October 15, 2018, the two complaints were consolidated (the “Consolidated Derivative Lawsuit”). On May 15, 2019, a consolidated amended complaint was filed. The consolidated amended complaint asserts claims for violation of Section 10(b), 14(a), and 29(b) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. Plaintiffs seek to recover damages on behalf of the Company, certain corporate governance and internal procedural reforms, and other equitable relief. The Court granted final approval to the settlement on February 19, 2021. Shareholder Lawsuits: Strougo, Cobb, and Delaware Lawsuits On February 25, 2020, Robert Strougo, claiming to be a stockholder of the Company, filed a complaint on behalf of stockholders who purchased Common Stock between March 8, 2019 and February 19, 2020 (the "Strougo Lawsuit"). The Strougo Lawsuit was filed as a class action in the U.S. District Court for the Middle District of Tennessee, naming the Company, the Company's chief financial officer and former chief executive officer as defendants. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act in making false and misleading statements and omissions related to the performance of the Nutrisystem business that the Company acquired on March 8, 2019. The complaint seeks monetary damages on behalf of the purported class. On August 18, 2020, the Court appointed Sheet Metal Workers Local No. 33, Cleveland District, Pension Fund as lead plaintiff. On April 9, 2020, John Cobb, claiming to be a stockholder of the Company, filed a derivative complaint in the United States District Court for the Middle District of Tennessee naming the Company as a nominal defendant and certain directors and the Company’s former chief executive officer and current chief financial officer as defendants (the “Cobb Lawsuit”). The complaint asserted claims for breach of Section 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, failure of internal controls, and unjust enrichment, largely tracking the factual allegations in the Strougo Lawsuit. The plaintiff seeks monetary damages on behalf of the Company, restitution, and certain corporate governance and internal procedural reforms. On June 9, 2020, the United States Magistrate Judge approved the parties’ stipulation to stay the case pending the resolution of defendants’ motion to dismiss in the Strougo Lawsuit. In July 2020, three putative derivative complaints were filed in the United States District Court for the District of Delaware by the following individuals claiming to be stockholders of the Company: Patrick Yerby, Thomas R. Conte, Melvyn Klein, and Mark Ridendour (the “Delaware Derivative Lawsuits”). The complaints largely track the allegations, named defendants, asserted claims, and requested relief of the Cobb Lawsuit. The three Delaware Derivative Lawsuits have been consolidated and stayed on terms similar to those entered in the Cobb Lawsuit. Given the uncertainty of litigation and the preliminary stage of the Strougo Lawsuit, Cobb Lawsuit, and Delaware Derivative Lawsuits, we are not currently able to predict the probable outcome of the matter or to reasonably estimate a range of potential loss, if any. We intend to vigorously defend ourselves against these lawsuits. Trademark Lawsuit: Pacific Packaging Lawsuit On May 31, 2019, Pacific Packaging Concepts, Inc. (“Pacific Packaging”) filed a complaint in the U.S. District Court for the Central District of California, Western Division, naming as defendants two subsidiaries of the Company; Nutrisystem, Inc. and Nutri/System IPHC, Inc. In its complaint, Pacific Packaging alleged that the defendants’ use of Pacific Packaging’s federally registered trademark, Fresh Start, in advertisements for its weight management program and shakes constitutes federal trademark infringement, counterfeit trademark infringement, false designation of origin, federal trademark dilution, unfair competition, false advertising, common law unfair competition, and common law trademark infringement. The complaint seeks injunctive relief and monetary damages in an unspecified amount. On August 29, 2019, the defendants filed their Answer to Complaint. The case is currently set for trial on April 20, 2021. In connection with the sale of Nutrisystem, the Company agreed to indemnify Kainos for losses arising out of this matter and retained the right to control the defense thereof. Given the uncertainty of litigation and the preliminary stage of the case, we are currently not able to predict the probable outcome of the matter or to reasonably estimate a range of potential loss, if any. We intend to vigorously defend ourselves against this complaint. Other Additionally, from time to time, we are subject to contractual disputes, claims and legal proceedings that arise in the ordinary course of our business. Some of the legal proceedings pending against us as of the date of this report are expected to be covered by insurance policies. As these matters are subject to inherent uncertainties, our view of these matters may change in the future. We expense legal costs as incurred

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	12 . Fai Valu We account for certain assets and liabilities at fair value. Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability. Fair Value Hierarchy The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: Level 1: Quoted prices in active markets for identical assets or liabilities; Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-based valuation techniques in which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3: Unobservable inputs that are supported by little or no market activity and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis We measure certain assets at fair value on a nonrecurring basis in the fourth quarter of each year, including the following: • reporting units measured at fair value as part of a goodwill impairment test; and • indefinite-lived intangible assets measured at fair value for impairment assessment. Each of these assets above is classified as Level 3 within the fair value hierarchy. The fair value of a reporting unit is the price that would be received upon a sale of the unit as a whole in an orderly transaction between market participants at the measurement date. Following the sale of Nutrisystem effective December 9, 2020, we have a single reporting unit. The COVID-19 pandemic has had and is having an adverse impact on the overall economy, resulting in rapidly changing market and economic conditions that have impacted the Company. In March 2020, we experienced a significant decline in our market capitalization and in our actual and forecasted operating results, in addition to the unfavorable change in market conditions. As a result, management concluded that there were triggering events during the first quarter of 2020 necessitating an impairment evaluation of our goodwill and indefinite-lived intangible assets (which consist of the Nutrisystem tradename and the SilverSneakers tradename). Following these evaluations, we recorded a total impairment loss of $199.5 million related to the Nutrisystem goodwill and tradename during the first quarter of 2020, which amount is reflected in loss from discontinued operations. We determined there was no impairment related to the SilverSneakers tradename or the carrying value of goodwill related to continuing operations. On October 18, 2020, we entered into the Purchase Agreement providing for the sale of the Nutrition business unit for $575.0 million (subject to the terms and conditions set forth in the Purchase Agreement), which indicated that the fair value for the Nutrition business unit was below its carrying value as of September 30, 2020. We performed an impairment assessment in accordance with the held and used model and determined that the fair values of all assets and liabilities allocated to the Nutrition segment approximated their carrying amounts as of September 30, 2020, except for goodwill. As a result, we recorded an impairment loss of $66.2 million for the third quarter of 2020 related to goodwill allocated to the former Nutrition segment, which amount is reflected in loss from discontinued operations. Effective December 9, 2020, we completed the sale of Nutrisystem to Kainos for an aggregate purchase price, after giving effect to customary indebtedness and cash adjustments, of approximately $558.9 million, which amount is subject to a customary working capital adjustment post-Closing. We estimate such working capital adjustment will result in additional proceeds to be received in 2021 of $2.8 million. At the time of disposition, the carrying value of the disposal group of $585.7 million exceeded the estimated gross proceeds (excluding our transaction costs) of $561.7 million. As a result, we recorded an additional impairment loss of $24.0 million in the fourth quarter of 2020 related to goodwill allocated to the former Nutrition segment, which amount During the fourth quarter of 2020, we reviewed goodwill for impairment related to our single reporting unit. We estimated the fair value of the o Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table presents our financial instruments measured at fair value on a recurring basis at December 31, 2020 and 2019. (In thousands) Level 2 December 31, 2020 December 31, 2019 Derivatives designated as effective hedging instruments Liabilities: Interest rate swap agreements $ 20,377 $ 16,238 Non-designated derivatives Liabilities: Interest rate swap agreements $ 16,260 $ — The fair values of interest rate swap agreements are primarily determined based on the present value of future cash flows using third-party pricing services with observable inputs, including interest rates, yield curves and applicable credit spreads. Fair Value of Other Financial Instruments The e a n n m a o Cash and cash equivalents – The carrying amount of $100.4 million approximates fair value because of the short maturity of those instruments (less than three months). Debt – The estimated fair value of outstanding borrowings under the Credit Agreement, which includes a revolving credit facility and a term loan facility (see Note 10), are determined based on the fair value hierarchy as discussed above. T he Term Loans are e o l i a e quotes as of December 31, 2020 from dealers who stand ready and willing to transact at those prices Th e volvin redi acilit The estimated net fair value and net carrying amount of outstanding borrowings under the Term Loans at December 31 , 2020 were $463.2 million and $466.7 million, respectively. There were no outstanding borrowings under the Revolving Credit Facility at December 31 , 2020.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Dec. 31, 2020
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	13 . Deri v v n n a n v We use derivative instruments to manage differences in the amount, timing, and duration of our known or expected cash payments related to our outstanding debt (i.e., interest rate risk). Some of these derivatives are designated and qualify as a hedge of the exposure to variability in expected future cash flows and are therefore considered cash flow hedges. We account for derivatives in accordance with FASB ASC Topic 815, which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet at fair value as either an asset or liability. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether we have elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Changes in the derivative’s fair value will be recognized currently in earnings unless specific hedge accounting criteria are met. We classify cash flows from settlement of our effective cash flow hedges in the same category as the cash flows from the related hedged items, generally within the operating activities in the consolidated statements of cash flows. We classify cash flows from settlement of our non-designated derivatives within the investing section of the consolidated statements of cash flows. Cash Flow Hedges of Interest Rate Risk and Non-Designated Derivatives Our objectives in using interest rate derivatives are to add stability to interest expense and to manage our exposure to interest rate movements. To accomplish these objectives, we primarily use interest rate swaps as part of our interest rate risk management strategy. The counterparties to the interest rate swap agreements expose us to credit risk in the event of nonperformance by such counterparties. However, at December 31, 2020, we do not anticipate nonperformance by these counterparties. Our interest rate swap agreements with each of the counterparties contain a provision whereby if we either default or are capable of being declared in default on any of our indebtedness, whether or not such default results in repayment of the indebtedness being accelerated by the lender, then we could also be declared in default on our derivative obligations. Derivative instruments designated as cash flow hedges must be de-designated as hedges when it is probable the forecasted hedged transaction will not occur in the initially identified time period or within a subsequent two-month time period. Deferred gains and losses in accumulated other comprehensive income or loss ("accumulated OCI") associated with such derivative instruments are reclassified into earnings in the period of de-designation. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for our making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. In May 2019, we entered into eight amortizing interest rate swap agreements, each of which matures in May 2024. Under these agreements, we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest equal to approximately 2.2% plus a spread (see Note 10). Upon entering into the Purchase Agreement with Kainos on October 18, 2020, we determined that some of our hedged transactions would not materially occur in the initially identified time period since we expected to use the majority of the net proceeds from the sale to pay down a significant portion of outstanding debt. As a result, we concluded that five of our eight interest rate swaps no longer qualified for hedge accounting treatment. Accordingly, in the fourth quarter of 2020 we de-designated these five derivatives (“de-designated swaps”) and accelerated the reclassification of deferred gains and losses in accumulated OCI to earnings as a result of the hedged forecasted transactions becoming probable not to occur. As a result of such acceleration upon de-designation, we recognized a pre-tax loss of $14.3 million in income (loss) from discontinued operations. Additionally, upon de-designation in October 2020, we froze $3.2 million of previously deferred losses in accumulated OCI related to forecasted payments that are probable of occurring. We reclassify such deferred losses from accumulated OCI into earnings as an adjustment to interest expense during periods in which the forecasted transactions impact earnings , consistent with hedge accounting treatment. In the event that the related forecasted payments are no longer probable of occurring, the related loss in accumulated OCI will be recognized in earnings immediately. We continue to maintain the effective hedging relationship between three interest rate swap agreements and the portion of our forecasted payments that is expected to remain highly probable of occurring. During the fourth quarter of 2020 we evaluated the likelihood and extent of potential future losses from the de-designated swaps. Such potential future losses are capped since the variable interest rate of our swaps is subject to a floor of 0%. Based on the LIBOR rates in effect at the time of de-designation, we decided to hold the de-designated swaps as derivative instruments requiring mark-to-market accounting treatment, with any change in fair value recognized each period in current earnings. At December 31, 2020, our interest rate swap agreements designated as effective cash flow hedges had current notional amounts totaling $388.9 million, and our de-designated interest rate swap agreements had current notional amounts totaling $311.1 million. We record all derivatives at estimated fair value in the consolidated balance sheet. Gains and losses on derivatives designated as effective cash flow hedges are recorded in accumulated OCI and subsequently reclassified into interest expense in the same period(s) during which the hedged transaction affects earnings. Amounts reported in accumulated OCI related to cash flow hedge derivatives will be reclassified to interest expense as we make interest payments on our variable-rate debt. As of December 31, 2020, we expect to reclassify $8.8 million from accumulated OCI as an increase to interest expense within the next 12 months due to the scheduled payment of interest associated with our debt. Gains and losses on derivatives de-designated as effective cash flow hedges are recorded in the consolidated statement of operations. The estimated gross fair values of derivative instruments and their classification on the consolidated balance sheet at December 31, 2020 and 2019 were as follows: (In thousands) December 31, 2020 December 31, 2019 Liabilities: Derivatives designated as effective hedging instruments: Current portion of long-term liabilities $ 8,205 $ 4,947 Other long-term liabilities 12,172 11,291 $ 20,377 $ 16,238 Non-designated derivatives: Current portion of long-term liabilities $ 6,548 $ — Other long-term liabilities 9,712 — $ 16,260 $ — The following table presents the effect of cash flow hedge accounting on accumulated OCI as of December 31, 2020 and 2019: (In thousands) For the Year Ended December 31, 2020 December 31, 2019 Derivatives designated as effective hedging instruments: Loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect 33,247 16,930 Loss related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect (11,556 ) (692 ) Non-designated derivatives: Loss related to de-designation of ineffective portion of derivatives, gross of tax effect (14,336 ) — Previously deferred loss reclassified from accumulated OCI to interest expense, gross of tax effect (239 ) — Total other comprehensive loss, gross of tax 7,116 16,238 The following table presents the impact that non-designated derivatives had on our consolidated statement of operations: (In thousands) Statement of Operations Classification Year Ended December 31, 2020 Loss related to de-designation of ineffective portion of derivatives, gross of tax effect Income from discontinued operations, net of income tax $ (14,336 ) Net loss related to ineffective portion of derivatives, gross of tax effect Selling, general and administrative expenses (226 ) Previously deferred loss related to de-designated swaps reclassified from accumulated OCI, gross of tax effect Interest expense (239 ) $ (14,801 )

Restructuring and Related charg

Restructuring and Related charges	12 Months Ended
	Dec. 31, 2020
Restructuring And Related Activities [Abstract]
Restructuring and Related Charges	14 . Restructuring and Related Charges 2019 Restructuring Plan During the first quarter of 2019, we began a reorganization primarily related to integrating the Nutrisystem business and streamlining our corporate and operations support (the "2019 Restructuring Plan"). The 2019 Restructuring Plan concluded during the first quarter of 2020. For the years ended December 31, 2020 and 2019, we incurred restructuring charges from continuing operations of $0.5 million and $1.9 million, respectively, related to the 2019 Restructuring Plan. To date, we have incurred restructuring charges from continuing operations of $2.4 million related to the 2019 Restructuring Plan. These expenses consist entirely of severance and other employee-related costs. 2020 COVID Restructuring Plan During the second quarter of 2020, we began a reorganization plan primarily related to eliminating certain compensation costs in response to the COVID-19 pandemic in order to preserve our liquidity and manage our cash flows (“2020 COVID Restructuring Plan”). The 2020 COVID Restructuring Plan was completed during the third quarter of 2020. To date and for the year ended December 31, 2020, we incurred restructuring charges from continuing operations of $0.8 million related to the 2020 COVID Restructuring Plan. These expenses consist entirely of severance and other employee-related costs. The 2020 COVID Restructuring Plan is expected to result in total annualized savings at target performance of approximately $6.0 million. 2020 Restructuring Plan During the third quarter of 2020, we began a reorganization plan primarily related to optimizing our business for growth and executing on our new strategy (“2020 Restructuring Plan”). To date and for the year ended December 31, 2020, we incurred restructuring charges from continuing operations of $3.1 million related to the 2020 Restructuring Plan, which consisted entirely of severance and other employee-related costs. Actions taken to date under the 2020 Restructuring Plan are expected to result in total annualized savings at target performance of approximately $6.7 million. The following table shows the activity from continuing operations in accrued restructuring and related charges for the year ended December 31 (In thousands) 2019 Restructuring Plan 2020 COVID Restructuring Plan 2020 Restructuring Plan Total Accrued restructuring and related charges liability as of January 1, 2020 $ 242 $ — $ — $ 242 Restructuring charges 475 816 2,327 3,618 Payments (606 ) (816 ) (514 ) (1,936 ) Accrued restructuring and related charges liability as of December 31, 2020 $ 111 $ — $ 1,813 $ 1,924

Earnings (Loss) Per Share

Earnings (Loss) Per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	15 . Earning (L o ss Pe Sha r Beginning in March 2019, we use the two-class method to calculate earnings per share as the unvested restricted stock awards outstanding under our equity incentive plan are participating shares with nonforfeitable rights to dividends. Under the two-class method, we compute earnings per share of common stock by dividing the sum of distributed earnings to common stockholders (currently not applicable as we do not pay dividends) and undistributed earnings allocated to common stockholders by the weighted average number of outstanding shares of common stock for the period. In applying the two-class method, we allocate undistributed earnings to both shares of common stock and participating securities based on the number of weighted average shares outstanding during the period. During periods of net loss, no effect is given to the participating securities because they do not share in the losses of the Company . The follow i ng is a r e c o ncili a tion of the n u merat o r a n d denom i nat o r of bas i c and d iluted earnin g s (l o s s) p e r share f o r the y ea r s end e d D e c e mber 3 1, 20 20 , 20 1 9 , and 201 8 : (In thousands except per share data) Year Ended December 31, Numerator: 2020 2019 2018 Income from continuing operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share $ 56,869 $ 45,217 $ 97,902 Net income (loss) from discontinued operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share (280,500 ) (332,038 ) 901 Net income (loss) attributable to Tivity Health, Inc. - numerator for earnings (loss) per share $ (223,631 ) $ (286,821 ) $ 98,803 Denominator: Shares used for basic income (loss) per share 48,746 46,509 40,078 Effect of dilutive stock options and restricted stock units outstanding: Non-qualified stock options 29 90 264 Restricted stock units 412 489 299 Performance-based stock units 29 15 — Warrants related to Cash Convertible Notes — — 2,013 Market stock units 1 — 419 Shares used for diluted income (loss) per share 49,217 47,103 43,073 Earnings (loss) per share attributable to Tivity Health, Inc. - basic: Continuing operations $ 1.17 $ 0.97 $ 2.44 Discontinued operations $ (5.75 ) $ (7.14 ) $ 0.02 Net income (loss) (1) $ (4.59 ) $ (6.17 ) $ 2.47 Earnings (loss) per share attributable to Tivity Health, Inc. - diluted: Continuing operations $ 1.16 $ 0.96 $ 2.27 Discontinued operations $ (5.70 ) $ (7.05 ) $ 0.02 Net income (loss) $ (4.54 ) $ (6.09 ) $ 2.29 Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive: Non-qualified stock options 186 70 56 Restricted stock units 242 192 36 Performance-based stock units 24 — — Restricted stock awards 26 102 — (1) Figures may not add due to rounding. Market stock units and performance-based stock units outstanding are considered contingently issuable shares, and certain of these market stock units and performance-based stock units were excluded from the calculations of diluted earnings per share for all periods presented because the performance criteria had not been met as of the end of the reporting periods.

Accumulated OCI

Accumulated OCI	12 Months Ended
	Dec. 31, 2020
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Accumulated OCI	16 . Accumulated OCI The following tables summarize the changes in accumulated OCI, net of tax, for the years ended December 31, 2019 and 2020. (In thousands) Interest Rate Swaps Accumulated OCI, net of tax, as of January 1, 2019 $ — Other comprehensive income (loss) before reclassifications, net of tax of $4,324 (12,606 ) Amounts reclassified from accumulated OCI, net of tax of $177 515 Accumulated OCI, net of tax, as of December 31, 2019 $ (12,091 ) Other comprehensive income (loss) before reclassifications, net of tax of $8,491 (24,756 ) Amounts reclassified from accumulated OCI, net of tax of $6,674 19,458 Accumulated OCI, net of tax, as of December 31, 2020 $ (17,389 ) The following table presents details about reclassifications out of accumulated OCI for the years ended December 31, 2020 and 2019: (In thousands) Year Ended December 31, 2020 Year Ended December 31, 2019 Statement of Operations Classification Interest rate swaps $ 11,795 $ 692 Interest expense (3,012 ) (177 ) Income tax 10,675 — Income from discontinued operations, net of income tax Total amounts reclassified from accumulated OCI $ 19,458 $ 515 Net of tax

Segment Disclosures and Concent

Segment Disclosures and Concentrations of Risk	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Segment Disclosures and Concentrations of Risk	17 . Segment Disclosures and Concentrations of Risk Following the sale of Nutrisystem in December 2020, the results of which have been classified as discontinued operations for all periods presented, we have one operating and reportable segment. Therefore, all required segment information can be found in the Consolidated Financial Statements. Our determination that we operate as a single segment is consistent with the financial information regularly viewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. Geographic Information Long-lived assets and revenue from external customers attributable to our operations in the United States accounted for 100% . Major Customers During 2020, we had three customers that each accounted for 10% or more of our revenues from continuing operations and individually comprised approximately 18%, 11%, and 10% of our revenues for 2020. No other customer accounted for 10% or more of our revenues in 2020. In addition, at December 31, 2020, we had two customers that each accounted for 10% or more of our accounts receivable, net and individually comprised approximately 26% and 33% of our consolidated accounts receivable, net at December 31, 2020. During 2019, we had three customers that each accounted for 10% or more of our revenues from continuing operations and individually comprised approximately 23%, 11%, and 11% of our revenues for 2019. No other customer accounted for 10% or more of our revenues in 2019. In addition, at December 31, 2019, we had three customers that each accounted for 10% or more or our accounts receivable, net and individually comprised approximately 36%, 19%, and 11% of our accounts receivable, net at December 31, 2019.

Quarterly Financial Information

Quarterly Financial Information (unaudited)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (unaudited)	18 . Qua r r na d The following tables contain selected unaudited statements of operations for each quarter of 2020 and 2019. As further discussed in Note 1, our results from continuing operations do not include the results of Nutrisystem, which we sold effective December 9, 2020. (In thousands, except per share data) Year Ended December 31, 2020 First Second Third Fourth (1) Revenues $ 159,692 $ 81,923 $ 95,481 $ 100,617 Gross margin 42,713 45,879 45,382 44,168 Income before income taxes 11,411 23,959 23,236 15,793 Income from continuing operations 8,275 17,202 16,750 14,642 Income (loss) from discontinued operations, net of income tax (206,381 ) 11,309 (59,168 ) (26,260 ) Net income (loss) (198,106 ) 28,511 (42,418 ) (11,618 ) Earnings per share – basic: Continuing operations (2) $ 0.17 $ 0.35 $ 0.34 $ 0.30 Discontinued operations (2) $ (4.25 ) $ 0.23 $ (1.21 ) $ (0.54 ) Net income (loss) (2) (3) $ (4.08 ) $ 0.59 $ (0.87 ) $ (0.24 ) Earnings per share – diluted: Continuing operations (2) $ 0.17 $ 0.35 $ 0.34 $ 0.29 Discontinued operations (2) $ (4.22 ) $ 0.23 $ (1.20 ) $ (0.53 ) Net income (loss) (2) (3) $ (4.05 ) $ 0.58 $ (0.86 ) $ (0.23 ) (In thousands, except per share data) Year Ended December 31, 2019 First (4) Second Third Fourth (5) Revenues $ 156,527 $ 157,480 $ 159,979 $ 159,080 Gross margin 42,303 44,903 46,852 47,271 Income before income taxes 3,486 15,743 22,864 23,417 Income (loss) from continuing operations (161 ) 10,837 16,688 17,853 Income (loss) from discontinued operations, net of income tax 4,375 7,299 (2,769 ) (340,943 ) Net income (loss) 4,214 18,136 13,919 (323,090 ) Earnings per share – basic: Continuing operations (2) $ — $ 0.23 $ 0.35 $ 0.37 Discontinued operations (2) $ 0.10 $ 0.15 $ (0.06 ) $ (7.06 ) Net income (loss) (2) $ 0.10 $ 0.38 $ 0.29 $ (6.69 ) Earnings per share – diluted: Continuing operations (2) $ — $ 0.22 $ 0.34 $ 0.37 Discontinued operations (2) $ 0.10 $ 0.15 $ (0.06 ) $ (6.97 ) Net income (loss) (2) (3) $ 0.10 $ 0.37 $ 0.29 $ (6.61 ) (1) Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses. (2) We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share. (3) Figures may not add due to rounding. (4) The impact of potentially dilutive securities for the three months ended March 31, 2019 was not considered because the impact on continuing operations would be anti-dilutive. (5) Income from continuing operations for the fourth quarter of 2019 includes acquisition, integration, and project costs totaling $4.3 million, which were primarily recorded to selling, general, and administrative expenses.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation	a. Principles of Consolidation – See discussion above regarding Nutrisystem and MeYou Health. We have eliminated all intercompany profits, transactions, and balances.
Cash and Cash Equivalents	b. Cash and Cash Equivalents - Cash and cash equivalents primarily include cash on deposit.
Accounts Receivable, net	c. Accounts Receivable, net - Accounts receivable includes billed and unbilled amounts. Billed receivables represent fees that are contractually due for services performed or products sold, net of allowances for doubtful accounts (reflected as selling, general and administrative expenses). Allowances for doubtful accounts were $0 at December 31, 2020 and 2019, respectively. Historically, we have experienced minimal instances of customer non-payment and therefore consider our accounts receivable to be collectible; however, we provide reserves, when appropriate, for doubtful accounts on a specific identification basis. Unbilled receivables were $5.7 million and $29.1 million at December 31, 2020 and 2019, respectively, and
Property and Equipment	d. Property and Equipment - Property and equipment is carried at cost and includes expenditures that increase value or extend useful lives. We recognize depreciation using the straight-line method over useful lives of three to seven years for computer software and hardware and four to seven years for furniture and office equipment, and three to five years for equipment. Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the life of the lease, which ranges from two to fifteen years. Depreciation expense, including depreciation of assets recorded under finance leases, for the years ended December 31, 2020, 2019, and 2018 was $9.9 million, $7.1 million, and $4.7 million, respectively.
Other Assets	e. Other Assets - Other assets consist primarily of 159,309 shares of common stock of Sharecare, Inc. which have a carrying value of $10.8 million and are accounted for as a cost method investment, and customer incentives. We have elected the measurement alternative to measure cost method investments that do not have a readily determinable fair value at cost less impairment, adjusted by observable price changes, with any fair value changes recognized in earnings.
Leases	f. Leases – On January 1, 2019, we adopted Accounting Standards Update (“ASU”) No. 2016-02 using the modified retrospective approach. We recognize right-of-use assets and lease liabilities for leases with contractual terms longer than twelve months, and we categorize such leases as either operating or finance. Finance leases are generally those leases that allow us to substantially utilize or pay for the entire asset over its estimated life. All other leases are categorized as operating leases. Our leases generally have remaining lease terms of one to 45 months, some of which include options to extend the lease for additional periods. Such extension options were not considered in the value of the asset or liability since it is not probable that we will exercise the options to extend. If applicable, allocations among lease and non-lease components would be achieved using relative fair values. Lease liabilities are recognized at the present value of the fixed lease payments, reduced by landlord incentives using a discount rate based on similarly secured borrowings available to us. Lease assets are recognized based on the initial present value of the fixed lease payments, reduced by landlord incentives, plus any direct costs from executing the leases. Leasehold improvements are capitalized at cost and amortized over the lesser of their expected useful life or the lease term. Costs associated with right-of-use assets are recognized on a straight-line basis within operating expenses over the term of the lease. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest method over the lease term. See Note 9 for further information on leases.
Intangible Assets	g. Intangible Assets - Intangible assets subject to amortization include acquired technology and distributor and provider networks, which we amortized on a straight-line basis over estimated useful lives ranging from three to ten years. All intangible assets related to continuing operations and subject to amortization were fully amortized at December 31, 2020 and 2019. We assess the potential impairment of intangible assets subject to amortization whenever events or changes in circumstances indicate that the carrying values may not be recoverable. If we determine that the carrying value of other identifiable intangible assets may not be recoverable, we calculate any impairment using an estimate of the asset's fair value based on the estimated price that would be received to sell the asset in an orderly transaction between market participants. Intangible assets related to continuing operations and not subject to amortization at December 31, 2020 and 2019 consist of a trade name of $29.0 million. We review indefinite-lived intangible assets for impairment on an annual basis (during the fourth quarter of our fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable. We estimate the fair value of our indefinite-lived tradename using the relief-from-royalty method, which requires us to estimate significant assumptions such as the long-term growth rates of future revenues associated with the tradename, the royalty rate for such revenue, the terminal growth rate of revenue, the tax rate, and a discount rate. Changes in these estimates and assumptions could materially affect the estimate of fair value for the tradename. See Note 6 for further information on intangible assets.
Goodwill	h. Goodwill - We recognize goodwill for the excess of the purchase price over the fair value of tangible and identifiable intangible net assets of businesses that we acquire. We review o mp e o e e i e o e o e t n i d i u u en t n e n that th carryin v lu ma no b r e cov e rab l e single As part of the annual impairment test o e m n i o a n w i i o a n i l During a quantitative review of goodwill, we estimate the fair value of the reporting unit based on a discounted cash flow model or a combination of a discounted cash flow model and market-based approaches, and we reconcile the fair value of the reporting unit to our consolidated market capitalization. If the fair value of the reporting unit exceeds its carrying amount, no impairment is indicated. If the fair value of the reporting unit is less than its carrying amount, impairment of goodwill is measured as the excess of the carrying amount over fair value. Estimating fair value requires significant judgments, including management's estimate of future cash flows of each reporting unit (which is dependent on internal forecasts of projected income), estimation of the long-term growth rates of future revenues for our reporting units, the terminal growth rate of revenue, the tax rate, and determination of our weighted average cost of capital, as well as relevant comparable company revenue and earnings multiples and market participant acquisition premium for the market-based fair value and potential goodwill impairment for each reporting unit
Accounts Payable	i. Accounts Payable - Accounts payable consists of short-term trade obligations and includes cash overdrafts attributable to disbursements not yet cleared by the bank.
Accrued Liabilities	j. Accrued Liabilities – Accrued liabilities primarily include amounts owed for estimated member visits to fitness network locations (which actual visit data is typically received approximately one month in arrears
Income Taxes	k. Income Taxes - We file a consolidated federal income tax return that includes all of our wholly owned subsidiaries. U.S. GAAP generally requires that we record deferred income taxes for the tax effect of differences between the book and tax bases of our assets and liabilities. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are expected to be realized. When we determine that it is more likely than not that we will be able to realize our deferred tax assets in the future, an adjustment to the deferred tax asset is made and reflected in income.
Revenue Recognition	l. Revenue Recognition - On January 1, 2018, we adopted ASU No. 2014-09 using the modified retrospective transition method applied to contracts that were not completed as of January 1, 2018. See Note 4 for a further discussion of revenue recognition.
Marketing Expense	m. Marketing Expense – Marketing expense includes media, advertising production, marketing, and promotional expenses and payroll-related expenses, including share-based payment arrangements, for personnel engaged in these activities. Media expense from continuing operations was $7.2 million, $7.1 million, and $1.0 million in 2020, 2019, and 2018, respectively. Internet advertising expense is recorded based on either the rate of delivery of a guaranteed number of impressions over the advertising contract term or on a cost per customer acquired, depending upon the terms. All other advertising costs are charged to expense as incurred or, in the case of production costs, the first time the advertising takes place. At December 31, 2020 and 2019, $0 million and $1.7 million, respectively, of costs have been prepaid for future advertisements and promotions within continuing operations.
Earnings (Loss) Per Share	n. Earnings (Loss) Per Share – Beginning in 2019, we use the two-class method to calculate earnings per share (“EPS”) as the unvested restricted stock awards outstanding under our equity incentive plan were participating shares with nonforfeitable rights to dividends. Under the two-class method, we compute earnings per share of common stock by dividing the sum of distributed earnings to common stockholders (not applicable as we do not pay dividends) and undistributed earnings allocated to common stockholders by the weighted average number of outstanding shares of common stock for the period. In applying the two-class method, we allocate undistributed earnings to both shares of common stock and participating securities based on the number of weighted average shares outstanding during the period. During periods of net loss, no effect is given to the participating securities because they do not share in the losses of the Company. See
Share-Based Compensation	o. Share-Based Compensation – We recognize all share-based payments to employees in the consolidated statements of operations over the required vesting period based on estimated fair values at the date of grant. See Note 7 for a further discussion of share-based compensation.
Derivative Instruments and Hedging Activities	p. Derivative Instruments and Hedging Activities – We generally use derivative instruments to add stability to interest expense and to manage our exposure to interest rate movements. We account for derivatives in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 815, which establishes accounting and reporting standards requiring that certain derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivative’s fair value will be recognized currently in earnings unless specific hedge accounting criteria are met. For derivatives that are designated and qualify as effective cash flow hedges, the unrealized gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive income (loss) and reclassified into earnings as interest expense when the hedged transaction affects earnings. If a derivative instrument ceases to be a highly effective hedge, we will discontinue hedge accounting prospectively for the affected derivative instrument. The application of the authoritative guidance could impact the volatility of earnings. See Note 13 for further information on derivative instruments and hedging activities.
Management Estimates	q. Management Estimates – In preparing our consolidated financial statements in conformity with U.S. GAAP, management must make estimates and assumptions that affect: (1) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and (2) the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Recent Relevant Accounting Standards	In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-04, “ Reference Rate Reform (“ASC 848”): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”. ASC 848 contains temporary optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform, such as a transition away from the use of LIBOR. ASC 848 was effective for the Company as of January 1, 2020. The provisions of ASC 848 are available through December 31, 2022, at which time the reference rate replacement activity is expected to have been completed. The provisions of ASC 848 must be applied at a Topic, Subtopic or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. The accounting relief provided by ASC 848 is applicable only to legacy contracts if the amendments made to the agreements are solely for reference rate reform activities. Modifications that are unrelated to reference rate reform will scope out a given contract. ASC 848 allows for different elections to be made at different points in time, and the timing of those elections will be documented as applicable. For the avoidance of doubt, we intend to reassess the elections of optional expedients and exceptions included within ASC 848 related to our hedging activities and will document the election of these items on a quarterly basis. In March 2020, we elected the expedient that allows us to assume that our hedged interest payments are probable of occurring regardless of any expected modification in their terms related to reference rate reform. In addition, we have the option to change the method of assessing effectiveness upon a change in the critical terms of the derivative or the hedged transactions and upon the end of relief under ASC 848. In June 2020, we elected to (i) continue the method of assessing effectiveness as documented in the original hedge documentation and (ii) apply the expedient wherein the reference rate on the hypothetical derivative matches the reference rate on the hedging instrument. We will also apply the aforementioned elections to any future designated cash flow hedging relationship. In October 2018, the FASB issued ASU 2018-16, "Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (“SOFR”) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes" (“ASU 2018-16”), which adds the OIS rate based on SOFR as a U.S. benchmark interest rate to facilitate the LIBOR to SOFR transition and provide lead time for entities to prepare for changes to interest rate risk hedging strategies. ASU 2018-16 is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. As of December 31, 2020, the benchmark interest rate in our existing interest rate swap agreements is LIBOR. The adoption of this standard did not have an impact on our financial position, results of operations, or cash flows . In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”), which changes the fair value measurement disclosure requirements of ASC 820. ASU 2018-13 is effective for fiscal years beginning on or after December 15, 2019, including interim periods therein, and is generally required to be applied retrospectively, except for certain components that are to be applied prospectively. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures In August 2018, the FASB issued ASU No. 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract,” which requires implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the arrangement, if those costs would be capitalized by the customer in a software licensing arrangement. This standard is effective for annual periods beginning after December 15, 2019, and interim periods within those fiscal years. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires companies to measure credit losses for financial assets held at the reporting date utilizing a methodology that reflects current expected credit losses over the lifetime of such assets. ASU 2016-13 was effective for the Company on January 1, 2020 and is generally required to be applied using the modified retrospective approach, with limited exceptions for specific instruments. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2020
Discontinued Operations And Disposal Groups [Abstract]
Summary of Aggregate Carrying Amounts of Major Classes of Assets and Liabilities Related to Disposition	The following table presents the aggregate carrying amounts of the major classes of assets and liabilities related to the disposition of the Nutrition business: (In thousands) December 31, 2019 Accounts receivable, net $ 13,402 Inventories 36,150 Prepaid expenses 10,515 Other current assets 95 Current assets of discontinued operation 60,162 Property and equipment, net 29,333 Right-of-use assets 17,624 Intangible assets, net 660,637 Goodwill, net 319,956 Other assets 746 Long-term assets of discontinued operation 1,028,296 Total assets of discontinued operation $ 1,088,458 Accounts payable $ 18,381 Accrued salaries and benefits 6,184 Accrued liabilities 18,024 Deferred revenue 10,911 Income taxes payable 5,383 Current portion of lease liabilities 5,857 Current liabilities of discontinued operation 64,740 Long-term lease liabilities 11,816 Long-term deferred tax liability 156,624 Other long-term liabilities 971 Long-term liabilities of discontinued operation 169,411 Total liabilities of discontinued operation $ 234,151
Summary of Financial Results Included in Income (Loss) from Discontinued Operations	The following table presents financial results of the Nutrition business included in “income (loss) from discontinued operations" for the years ended December 31, 2020 and 2019. Results of operations for the year ended December 31, 2018 for the Nutrition business are not included as the Company did not acquire the Nutrition business until March 8, 2019, and there is no impact of the sale on the year ended December 31, 2018. Year Ended December 31 (In thousands) 2020 (1) 2019 (2) Revenues $ 617,191 $ 498,091 Cost of revenues 291,097 232,240 Marketing expenses 196,952 140,286 Selling, general and administrative expenses 59,093 56,840 Depreciation and amortization 35,957 43,638 Impairment loss 199,500 377,100 Restructuring and related charges 472 5,143 Interest expense (3) 36,798 34,763 Pretax loss from discontinued operations (202,678 ) (391,919 ) Loss on de-designation of cash flow hedges (4) (14,336 ) — Write-off of deferred loan costs and debt discount (3) (8,946 ) — Loss on sale of Nutrition business (5) (101,391 ) — Total pretax loss on discontinued operations $ (327,351 ) $ (391,919 ) Income tax benefit (46,851 ) (59,881 ) Loss from discontinued operations, net of income tax benefit $ (280,500 ) $ (332,038 ) (1) Results include the period from January 1, 2020 through December 8, 2020. (2) Results include the period from March 8, 2019 (the date of acquisition) through December 31, 2019. (3) The term loans under our Credit Agreement were originated with the purchase of Nutrisystem on March 8, 2019. Following the disposition of Nutrisystem, we repaid $519.0 million of principal on the Term Loans under the terms of the Credit Agreement. In conjunction with the partial debt prepayment, we wrote off a portion of the related deferred loan costs and original issue discount. We allocated interest expense to discontinued operations based on the interest expense incurred from March 8, 2019 through December 8, 2020 related to $519.0 million of term loan debt, using our historical interest rates. (4) Represents loss recognized in the fourth quarter of 2020 in connection with the de-designation of cash flow hedging on interest rate swaps (see Note 13). (5) Consists of impairment losses of $90.2 million related to Nutrisystem goodwill (see Note 12), which includes post-Closing adjustments related to final settlement, and $11.2 million of transaction costs directly related to the disposition of Nutrisystem.
Summary of Depreciation, Amortization and Significant Operating and Investing Non-cash Items of the Discontinued Operations	The depreciation, amortization and significant operating and investing non-cash items of the discontinued operations were as follows: Year Ended December 31 (In thousands) 2020 2019 Impairment of goodwill and intangible assets $ 199,500 $ 377,100 Loss on sale of business 90,163 — Depreciation and amortization 35,957 43,638 Loss on de-designation of cash flow hedges 14,336 — Write-off of deferred loan costs and debt discount (1) 8,946 — Capital expenditures on discontinued operations 6,794 10,168 Share-based compensation on discontinued operations 4,351 13,230 Deferred income taxes (54,561 ) (68,488 ) (1) Reflected on the consolidated statement of cash flows in the line items “Amortization and write-off of deferred loan costs” and “Amortization and write-off of debt discount”.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Summary of Revenue Disaggregated	The following table sets forth revenue from continuing operations disaggregated by program. Revenue from our SilverSneakers program is predominantly contracted with Medicare Advantage and Medicare Supplement plans. (In thousands) Year Ended December 31 2020 2019 2018 SilverSneakers $ 313,575 $ 492,778 $ 487,559 Prime Fitness 95,015 120,949 101,391 WholeHealth Living 19,776 18,511 16,835 Other (1) 9,348 828 514 $ 437,714 $ 633,066 $ 606,299 (1) For the year ended December 31, 2020, other revenue in the table above includes $6.8 million from a well-being program with a large employer (which we do not expect to recur at this level) and $2.2 million from our Wisely Well program.

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment at December 31, 2020 and 2019 consisted of the following: (In thousands) December 31, 2020 December 31, 2019 Leasehold improvements $ 7,963 $ 7,659 Computer equipment and related software 45,504 30,256 Furniture and office equipment 4,418 6,173 Capital projects in process 1,262 12,020 Total property and equipment at cost $ 59,147 $ 56,108 Less: accumulated depreciation (38,188 ) (32,532 ) Total property and equipment, net $ 20,959 $ 23,576

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets Subject to Amortization	Intangible assets subject to amortization at December 31, 2020 and 2019 consisted of the following: (In thousands) Gross Carrying Amount Accumulated Amortization Net Acquired technology $ 1,483 $ (1,483 ) — Distributor and provider networks 8,709 (8,709 ) — Total $ 10,192 $ (10,192 ) $ —

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Allocated Share-based Compensation Costs	Following are certain amounts recognized in the consolidated statements of operations for share-based compensation arrangements for the years ended December 31, 2020, 2019, and 2018. We did not capitalize any share-based compensation costs during these periods. Year Ended December December December 31, (In millions) 2020 2019 2018 Share-based compensation included in cost of revenue $ 2.7 $ 2.2 $ 2.3 Share-based compensation included in selling, general and administrative expenses 6.2 3.4 3.8 Share-based compensation included in restructuring and related charges 0.8 — — Share-based compensation included in continuing operations $ 9.7 $ 5.6 $ 6.1 Share-based compensation included in discontinued operations 4.4 13.2 — Total share-based compensation $ 14.1 $ 18.8 $ 6.1 Total income tax benefit recognized in continuing operations 2.5 1.4 1.6
Summary of Weighted Average Grant-date Fair Values of Options and Weighted Average Assumptions Used to Develop Fair Value Estimates	The following table sets forth the weighted average grant-date fair values of options and the weighted average assumptions we used to develop the fair value estimates for the years ended December 31, 2020 and 2018. There were no stock options granted during fiscal 2019. Year Ended December 2020 Year Ended December 2019 Year Ended December 2018 Weighted average grant-date fair value of options per share $ 8.20 $ — $ 20.21 Assumptions: Expected volatility 63.2 % — 56.2 % Expected dividends — — — Expected term (in years) 6.2 — 6.7 Risk-free rate 0.7 % — 2.8 %
Summary of Stock Options	A summary of options as of December 31, 2020 and the activity during the year then ended is presented below: Options Shares (In Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding at January 1, 2020 319 $ 17.85 Granted 220 16.78 Exercised (81 ) 12.67 Forfeited (5 ) 39.55 Expired (31 ) 20.76 Outstanding at December 31, 2020 422 $ 17.83 5.2 $ 1,544 Exercisable at December 31, 2020 187 $ 17.54 3.0 $ 927
Summary of Restricted Stock Awards	The following table shows a summary of our restricted stock awards as of December 31, 2020, as well as activity during the year then ended: Restricted Stock Awards Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2020 127 $ 19.42 Vested (120 ) 19.42 Forfeited (7 ) 19.42 Nonvested at December 31, 2020 — $ —
Summary of Restricted Stock Units	The following table shows a summary of our restricted stock units as of December 31, 2020 as well as activity during the year then ended: Restricted Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2020 393 $ 21.16 Granted 1,774 11.17 Vested (692 ) 13.81 Forfeited (234 ) 17.96 Nonvested at December 31, 2020 1,241 $ 11.58
Summary of Performance-Based Stock Units	The following table shows a summary of our performance-based stock units as of December 31, 2020, as well as activity during the year then ended: Performance Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2020 407 $ 20.29 Granted 4 21.49 Shares adjustment for performance (1) (74 ) 20.26 Vested (86 ) 20.42 Forfeited (165 ) 20.26 Nonvested at December 31, 2020 86 $ 20.30 (1) Represents the number of shares at target for certain performance-based stock units that are no longer eligible to be earned as a result of actual performance being below the applicable performance targets. These awards are included in the nonvested balance at January 1, 2020 and the number of shares granted above.
Summary of Market Stock Units	The following table shows a summary of our market stock units as of December 31, 2020 as well as activity during the year then ended: Market Stock Units Shares (In thousands) Weighted- Average Grant Date Fair Value Nonvested at January 1, 2020 — $ — Granted 150 18.84 Nonvested at December 31, 2020 150 $ 18.84

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Components of Income Tax Expense	Income tax expense is comprised of the following: Year Ended December 31, (In thousands) 2020 2019 2018 Current taxes: Federal $ 526 $ 3,051 $ 29 State 881 830 1,857 Deferred taxes: Federal 14,114 11,853 20,136 State 2,009 4,559 5,024 Total $ 17,530 $ 20,293 $ 27,046
Significant Components of Net Deferred Tax Asset and Liability	The following table sets forth the significant components of our net deferred tax asset and liability as of December 31, 2020 and 2019: (In thousands) December 31, 2020 December 31, 2019 Deferred tax asset: Accruals and reserves $ 1,137 $ 498 Deferred compensation 604 191 Share-based payments 2,909 2,802 Lease liability 4,993 5,003 Section 163(j) interest limitation 370 5,647 Interest rate swap 5,964 4,147 Unrealized losses 3,720 — Net operating loss carryforwards 10,608 7,200 Capital loss carryforwards 149,608 7,801 179,913 33,289 Valuation allowance (152,295 ) (13,147 ) $ 27,618 $ 20,142 Deferred tax liability: Property and equipment $ (4,516 ) $ (3,181 ) Intangible assets (14,868 ) (14,651 ) Right-of-use assets (4,633 ) (6,532 ) (24,017 ) (24,364 ) Net long-term deferred tax asset (liability) $ 3,601 $ (4,222 )
Difference between Income Tax Expense Computed using Statutory Federal Income Tax Rate and effective rate	The difference between income tax expense computed using the statutory federal income tax rate and the effective rate is as follows: Year Ended December 31, (In thousands) 2020 2019 2018 Statutory federal income tax $ 15,624 $ 13,757 $ 26,239 State income taxes, less federal income tax benefit 3,607 3,048 6,261 Permanent items 1,131 306 1,496 Change in valuation allowance (2,659 ) 2,509 (1,005 ) Share-based compensation 426 210 (6,378 ) State income tax credits — 954 677 Change in uncertain tax position liability — — (644 ) Prior year tax adjustments (592 ) (464 ) (590 ) Net impact of foreign operations 3 (9 ) 990 Other (10 ) (18 ) — Income tax expense $ 17,530 $ 20,293 $ 27,046
Changes in Unrecognized Tax Benefits	The aggregate changes in the balance of unrecognized tax benefits, exclusive of interest, were as follows: (In thousands) Unrecognized tax benefits at December 31, 2018 $ — Increases related to acquisition of Nutrisystem 1,006 Increases related to current year tax positions 8 Increases related to prior year tax positions 66 Decreases due to lapse of statute of limitations (19 ) Unrecognized tax benefits at December 31, 2019 $ 1,061 Increases related to prior year tax positions 84 Decreases due to lapse of statute of limitations (20 ) Decreases related to Nutrisystem divestiture (1,125 ) Unrecognized tax benefits at December 31, 2020 $ —

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of Right-of-Use Assets and Lease Liabilities	The following table shows the right-of-use assets and lease liabilities recorded on the balance sheet: December 31, 2020 December 31, 2019 (In thousands) Right-of-use assets: Operating $ 17,145 $ 23,895 Finance 994 1,680 Total leased assets $ 18,139 $ 25,575 Lease liabilities: Current Operating $ 7,408 $ 7,274 Finance 644 624 Non-current Operating $ 11,097 $ 18,505 Finance 397 1,080 Total lease liabilities $ 19,546 $ 27,483
Schedule of Components of Lease Expense	The following table shows the components of lease expense: Year Ended December 31, Year Ended December 31, (In thousands) 2020 2019 Finance lease cost: Amortization of leased assets $ 686 $ 298 Interest of lease liabilities 86 51 Operating lease cost 7,872 8,817 Total lease cost before subleases $ 8,644 $ 9,166 Sublease income (5,452 ) (5,479 ) Total lease cost, net $ 3,192 $ 3,687
Schedule of Weighted Average Remaining Term and Discount Rates	The following provides information related to the lease term and discount rate as of December 31, 2020: Weighted Average Remaining Lease Term (years) Operating leases 2.6 Finance leases 1.6 Weighted Average Discount Rate Operating leases 4.8 % Finance leases 5.9 %
Schedule of Maturities of Lease Liabilities	As of December 31 aturities of lease liabilities for each of the next five years and thereafter were as follows: Operating Leases Financing (In thousands) Lease Payments Sublease Receipts Net Leases 2021 8,115 (5,699 ) 2,416 686 2022 7,957 (5,732 ) 2,225 403 2023 2,518 (957 ) 1,561 — 2024 1,083 — 1,083 — Total lease payments 19,673 $ (12,388 ) $ 7,285 1,089 Less: interest (1,168 ) (48 ) Present value of lease liabilities $ 18,505 $ 1,041
Schedule of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was as follows: Year Ended December 31, Year Ended December 31, (In thousands) 2020 2019 Cash paid for amounts included in the measurement of lease liabilities Operating cash flow attributable to operating leases $ (3,492 ) $ (4,626 ) Operating cash flow attributable to finance leases (86 ) (51 ) Financing cash flow attributable to finance leases (622 ) (274 ) Supplemental noncash information: Right-of-use assets obtained in exchange for operating lease liabilities (1) — 31,538 Right-of-use assets obtained in exchange for finance lease liabilities (2) — 1,978 (1) No new operating leases were entered into during the year ended December 31, 2019. Amount shown is due to the adoption of ASC 842 and one lease modification that resulted in a noncash remeasurement of the related right-of-use asset and operating lease liability. Amount shown reflects balance as of January 1, 2019, adjusted for lease modification. (2) Amount shown is due to the adoption of ASC 842 and one new finance lease for $1.8 million entered into during the year ended December 31, 2019. In addition to such lease, amount shown reflects balance as of January 1, 2019.

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount	The Company's debt, net of unamortized deferred loan costs and original issue discount, consisted of the following at December 31, 2020 and 2019: (In thousands) December 31, 2020 December 31, 2019 Term Loan A $ 124,035 $ 288,750 Term Loan B 372,240 786,250 Revolving credit facility — 19,850 496,275 1,094,850 Less: deferred loan costs and original issue discount (29,569 ) (46,723 ) Total debt 466,706 1,048,127 Less: current portion (1) (7,456 ) — Total long-term debt $ 459,250 $ 1,048,127 (1) Represents additional term loan principal due upon final settlement of the sale of Nutrisystem based on the estimated post-Closing adjustments.
Minimum Annual Principal Payments and Repayments of the Revolving Advances	The following table summarizes the minimum annual principal payments and repayments of the revolving advances under the Credit Agreement for each of the next five years and thereafter: (In thousands) Year ending December 31, 2021 $ 7,456 (1) 2022 59,900 2023 59,900 2024 77,071 2025 24,900 2026 and thereafter 267,048 Total $ 496,275 (1) The total term loan principal due during 2021 reflects $7.5 million of additional debt repayment required upon estimated final settlement of the Nutrisystem sale.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table presents our financial instruments measured at fair value on a recurring basis at December 31, 2020 and 2019. (In thousands) Level 2 December 31, 2020 December 31, 2019 Derivatives designated as effective hedging instruments Liabilities: Interest rate swap agreements $ 20,377 $ 16,238 Non-designated derivatives Liabilities: Interest rate swap agreements $ 16,260 $ —

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	12 Months Ended
	Dec. 31, 2020
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Schedule of Estimated Gross Fair Values of Derivative Instruments and Their Classification on Consolidated Balance Sheet	The estimated gross fair values of derivative instruments and their classification on the consolidated balance sheet at December 31, 2020 and 2019 were as follows: (In thousands) December 31, 2020 December 31, 2019 Liabilities: Derivatives designated as effective hedging instruments: Current portion of long-term liabilities $ 8,205 $ 4,947 Other long-term liabilities 12,172 11,291 $ 20,377 $ 16,238 Non-designated derivatives: Current portion of long-term liabilities $ 6,548 $ — Other long-term liabilities 9,712 — $ 16,260 $ —
Schedule of Effect of Cash Flow Hedge Accounting on Accumulated OCI	The following table presents the effect of cash flow hedge accounting on accumulated OCI as of December 31, 2020 and 2019: (In thousands) For the Year Ended December 31, 2020 December 31, 2019 Derivatives designated as effective hedging instruments: Loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect 33,247 16,930 Loss related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect (11,556 ) (692 ) Non-designated derivatives: Loss related to de-designation of ineffective portion of derivatives, gross of tax effect (14,336 ) — Previously deferred loss reclassified from accumulated OCI to interest expense, gross of tax effect (239 ) — Total other comprehensive loss, gross of tax 7,116 16,238
Schedule of Impact of Derivatives Not Designated as Hedges on Consolidated Statement of Operations	The following table presents the impact that non-designated derivatives had on our consolidated statement of operations: (In thousands) Statement of Operations Classification Year Ended December 31, 2020 Loss related to de-designation of ineffective portion of derivatives, gross of tax effect Income from discontinued operations, net of income tax $ (14,336 ) Net loss related to ineffective portion of derivatives, gross of tax effect Selling, general and administrative expenses (226 ) Previously deferred loss related to de-designated swaps reclassified from accumulated OCI, gross of tax effect Interest expense (239 ) $ (14,801 )

Restructuring and Related cha_2

Restructuring and Related charges (Tables)	12 Months Ended
	Dec. 31, 2020
Restructuring And Related Activities [Abstract]
Schedule of Accrued Restructuring and Related Charges Activity	The following table shows the activity from continuing operations in accrued restructuring and related charges for the year ended December 31 (In thousands) 2019 Restructuring Plan 2020 COVID Restructuring Plan 2020 Restructuring Plan Total Accrued restructuring and related charges liability as of January 1, 2020 $ 242 $ — $ — $ 242 Restructuring charges 475 816 2,327 3,618 Payments (606 ) (816 ) (514 ) (1,936 ) Accrued restructuring and related charges liability as of December 31, 2020 $ 111 $ — $ 1,813 $ 1,924

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share	The follow i ng is a r e c o ncili a tion of the n u merat o r a n d denom i nat o r of bas i c and d iluted earnin g s (l o s s) p e r share f o r the y ea r s end e d D e c e mber 3 1, 20 20 , 20 1 9 , and 201 8 : (In thousands except per share data) Year Ended December 31, Numerator: 2020 2019 2018 Income from continuing operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share $ 56,869 $ 45,217 $ 97,902 Net income (loss) from discontinued operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share (280,500 ) (332,038 ) 901 Net income (loss) attributable to Tivity Health, Inc. - numerator for earnings (loss) per share $ (223,631 ) $ (286,821 ) $ 98,803 Denominator: Shares used for basic income (loss) per share 48,746 46,509 40,078 Effect of dilutive stock options and restricted stock units outstanding: Non-qualified stock options 29 90 264 Restricted stock units 412 489 299 Performance-based stock units 29 15 — Warrants related to Cash Convertible Notes — — 2,013 Market stock units 1 — 419 Shares used for diluted income (loss) per share 49,217 47,103 43,073 Earnings (loss) per share attributable to Tivity Health, Inc. - basic: Continuing operations $ 1.17 $ 0.97 $ 2.44 Discontinued operations $ (5.75 ) $ (7.14 ) $ 0.02 Net income (loss) (1) $ (4.59 ) $ (6.17 ) $ 2.47 Earnings (loss) per share attributable to Tivity Health, Inc. - diluted: Continuing operations $ 1.16 $ 0.96 $ 2.27 Discontinued operations $ (5.70 ) $ (7.05 ) $ 0.02 Net income (loss) $ (4.54 ) $ (6.09 ) $ 2.29 Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive: Non-qualified stock options 186 70 56 Restricted stock units 242 192 36 Performance-based stock units 24 — — Restricted stock awards 26 102 — (1) Figures may not add due to rounding.

Accumulated OCI (Tables)

Accumulated OCI (Tables)	12 Months Ended
	Dec. 31, 2020
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Changes in Accumulated OCI	The following tables summarize the changes in accumulated OCI, net of tax, for the years ended December 31, 2019 and 2020. (In thousands) Interest Rate Swaps Accumulated OCI, net of tax, as of January 1, 2019 $ — Other comprehensive income (loss) before reclassifications, net of tax of $4,324 (12,606 ) Amounts reclassified from accumulated OCI, net of tax of $177 515 Accumulated OCI, net of tax, as of December 31, 2019 $ (12,091 ) Other comprehensive income (loss) before reclassifications, net of tax of $8,491 (24,756 ) Amounts reclassified from accumulated OCI, net of tax of $6,674 19,458 Accumulated OCI, net of tax, as of December 31, 2020 $ (17,389 )
Schedule of Reclassifications Out of Accumulated OCI	The following table presents details about reclassifications out of accumulated OCI for the years ended December 31, 2020 and 2019: (In thousands) Year Ended December 31, 2020 Year Ended December 31, 2019 Statement of Operations Classification Interest rate swaps $ 11,795 $ 692 Interest expense (3,012 ) (177 ) Income tax 10,675 — Income from discontinued operations, net of income tax Total amounts reclassified from accumulated OCI $ 19,458 $ 515 Net of tax

Quarterly Financial Informati_2

Quarterly Financial Information (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following tables contain selected unaudited statements of operations for each quarter of 2020 and 2019. As further discussed in Note 1, our results from continuing operations do not include the results of Nutrisystem, which we sold effective December 9, 2020. (In thousands, except per share data) Year Ended December 31, 2020 First Second Third Fourth (1) Revenues $ 159,692 $ 81,923 $ 95,481 $ 100,617 Gross margin 42,713 45,879 45,382 44,168 Income before income taxes 11,411 23,959 23,236 15,793 Income from continuing operations 8,275 17,202 16,750 14,642 Income (loss) from discontinued operations, net of income tax (206,381 ) 11,309 (59,168 ) (26,260 ) Net income (loss) (198,106 ) 28,511 (42,418 ) (11,618 ) Earnings per share – basic: Continuing operations (2) $ 0.17 $ 0.35 $ 0.34 $ 0.30 Discontinued operations (2) $ (4.25 ) $ 0.23 $ (1.21 ) $ (0.54 ) Net income (loss) (2) (3) $ (4.08 ) $ 0.59 $ (0.87 ) $ (0.24 ) Earnings per share – diluted: Continuing operations (2) $ 0.17 $ 0.35 $ 0.34 $ 0.29 Discontinued operations (2) $ (4.22 ) $ 0.23 $ (1.20 ) $ (0.53 ) Net income (loss) (2) (3) $ (4.05 ) $ 0.58 $ (0.86 ) $ (0.23 ) (In thousands, except per share data) Year Ended December 31, 2019 First (4) Second Third Fourth (5) Revenues $ 156,527 $ 157,480 $ 159,979 $ 159,080 Gross margin 42,303 44,903 46,852 47,271 Income before income taxes 3,486 15,743 22,864 23,417 Income (loss) from continuing operations (161 ) 10,837 16,688 17,853 Income (loss) from discontinued operations, net of income tax 4,375 7,299 (2,769 ) (340,943 ) Net income (loss) 4,214 18,136 13,919 (323,090 ) Earnings per share – basic: Continuing operations (2) $ — $ 0.23 $ 0.35 $ 0.37 Discontinued operations (2) $ 0.10 $ 0.15 $ (0.06 ) $ (7.06 ) Net income (loss) (2) $ 0.10 $ 0.38 $ 0.29 $ (6.69 ) Earnings per share – diluted: Continuing operations (2) $ — $ 0.22 $ 0.34 $ 0.37 Discontinued operations (2) $ 0.10 $ 0.15 $ (0.06 ) $ (6.97 ) Net income (loss) (2) (3) $ 0.10 $ 0.37 $ 0.29 $ (6.61 ) (1) Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses. (2) We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share. (3) Figures may not add due to rounding. (4) The impact of potentially dilutive securities for the three months ended March 31, 2019 was not considered because the impact on continuing operations would be anti-dilutive. (5) Income from continuing operations for the fourth quarter of 2019 includes acquisition, integration, and project costs totaling $4.3 million, which were primarily recorded to selling, general, and administrative expenses.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	Jan. 01, 2018USD ($)	Dec. 31, 2020USD ($)ProgramSegmentshares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)
Accounting Policies [Line Items]
Number of programs | Program		4
Increase to deferred revenue	$ 3,200	$ 686	$ (1,198)
Decrease to retained earnings	$ 3,200
Allowance for doubtful accounts		0	0
Unbilled receivables		5,700	29,100
Depreciation expense		$ 9,930	$ 7,137	$ 4,667
Common stock shares | shares		48,983,735	48,156,786
Carrying value of adjustable convertible equity right		$ 10,800
Number of reporting units | Segment		1
Accrued liabilities		$ 18,424	$ 37,640
Continuing Operations
Accounting Policies [Line Items]
Number of programs | Program		3
Increase to deferred revenue		$ 3,800
Number of reporting units | Segment		1
Media expense		$ 7,200	7,100	1,000
Prepaid for future advertisements and promotions		$ 0	1,700
Healthcare
Accounting Policies [Line Items]
Intangible assets not subject to amortization			29,000	$ 29,000
Number of reporting units | Segment		1
Other Assets
Accounting Policies [Line Items]
Common stock shares | shares		159,309
Network Locations Visits
Accounting Policies [Line Items]
Accrued liabilities		$ 10,500	$ 28,800
Minimum
Accounting Policies [Line Items]
Remaining lease terms		1 month
Estimated useful life		3 years	3 years
Maximum
Accounting Policies [Line Items]
Remaining lease terms		45 months
Estimated useful life		10 years	10 years
Computer Software and Hardware | Minimum
Accounting Policies [Line Items]
Useful life		3 years
Computer Software and Hardware | Maximum
Accounting Policies [Line Items]
Useful life		7 years
Furniture and Office Equipment | Minimum
Accounting Policies [Line Items]
Useful life		4 years
Furniture and Office Equipment | Maximum
Accounting Policies [Line Items]
Useful life		7 years
Equipment | Minimum
Accounting Policies [Line Items]
Useful life		3 years
Equipment | Maximum
Accounting Policies [Line Items]
Useful life		5 years
Leasehold Improvements | Minimum
Accounting Policies [Line Items]
Useful life		2 years
Leasehold Improvements | Maximum
Accounting Policies [Line Items]
Useful life		15 years

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2018	Dec. 09, 2020
Business Acquisition [Line Items]
Proceeds from sale of business, net of cash transferred	$ 558,067	$ 1,416
Nutrisystem, Inc.
Business Acquisition [Line Items]
Customary indebtedness and cash adjustments			$ 558,900
Transaction costs directly related to disposition of Nutrition	11,200
Proceeds from sale of business, net of cash transferred	550,500
Nutrisystem, Inc. | Other Current Assets
Business Acquisition [Line Items]
Additional proceeds from sale of businesses after working capital adjustment	$ 2,800

Discontinued Operations - Summa

Discontinued Operations - Summary of Aggregate Carrying Amounts of Major Classes of Assets and Liabilities Related to Disposition (Details) - USD ($) $ in Thousands	Dec. 09, 2020	Dec. 31, 2019
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Current assets of discontinued operation		$ 60,162
Long-term assets of discontinued operation		1,028,296
Current liabilities of discontinued operation		64,740
Long-term liabilities of discontinued operation		169,411
Nutrisystem, Inc.
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Accounts receivable, net		13,402
Inventories		36,150
Prepaid expenses		10,515
Other current assets		95
Current assets of discontinued operation		60,162
Property and equipment, net		29,333
Right-of-use assets		17,624
Intangible assets, net		660,637
Goodwill, net		319,956
Other assets		746
Long-term assets of discontinued operation		1,028,296
Total assets of discontinued operation	$ 585,700	1,088,458
Accounts payable		18,381
Accrued salaries and benefits		6,184
Accrued liabilities		18,024
Deferred revenue		10,911
Income taxes payable		5,383
Current portion of lease liabilities		5,857
Current liabilities of discontinued operation		64,740
Long-term lease liabilities		11,816
Long-term deferred tax liability		156,624
Other long-term liabilities		971
Long-term liabilities of discontinued operation		169,411
Total liabilities of discontinued operation		$ 234,151

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Financial Results Included in Income (Loss) from Discontinued Operations (Details) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
		Mar. 31, 2020	Dec. 31, 2020		Dec. 31, 2019		Dec. 31, 2018
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Impairment loss			$ 199,500		$ 377,100
Write-off of deferred loan costs and debt discount	[1]		(8,946)
Discontinued operation, income tax (benefit)			(46,851)		(59,881)		$ 325
Loss from discontinued operations, net of income tax benefit			(280,500)		(332,038)		$ 901
Nutrisystem, Inc.
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Revenues			617,191	[2]	498,091	[3]
Cost of revenues			291,097	[2]	232,240	[3]
Marketing expenses			196,952	[2]	140,286	[3]
Selling, general and administrative expenses			59,093	[2]	56,840	[3]
Depreciation and amortization			35,957	[2]	43,638	[3]
Impairment loss		$ 199,500	199,500	[2]	377,100	[3]
Restructuring and related charges			472	[2]	5,143	[3]
Interest expense	[4]		36,798	[2]	34,763	[3]
Pretax loss from discontinued operations			(202,678)	[2]	(391,919)	[3]
Loss on de-designation of cash flow hedges	[2],[5]		(14,336)
Write-off of deferred loan costs and debt discount	[2],[4]		(8,946)
Loss on sale of Nutrition business	[2],[6]		(101,391)
Total pretax loss on discontinued operations			(327,351)	[2]	(391,919)	[3]
Discontinued operation, income tax (benefit)			(46,851)	[2]	(59,881)	[3]
Loss from discontinued operations, net of income tax benefit			$ (280,500)	[2]	$ (332,038)	[3]
[1]	Reflected on the consolidated statement of cash flows in the line items “Amortization and write-off of deferred loan costs” and “Amortization and write-off of debt discount”.
[2]	Results include the period from January 1, 2020 through December 8, 2020.
[3]	Results include the period from March 8, 2019 (the date of acquisition) through December 31, 2019.
[4]	The term loans under our Credit Agreement were originated with the purchase of Nutrisystem on March 8, 2019. Following the disposition of Nutrisystem, we repaid $519.0 million of principal on the Term Loans under the terms of the Credit Agreement. In conjunction with the partial debt prepayment, we wrote off a portion of the related deferred loan costs and original issue discount. We allocated interest expense to discontinued operations based on the interest expense incurred from March 8, 2019 through December 8, 2020 related to $519.0 million of term loan debt, using our historical interest rates.
[5]	Represents loss recognized in the fourth quarter of 2020 in connection with the de-designation of cash flow hedging on interest rate swaps (see Note 13).
[6]	Consists of impairment losses of $90.2 million related to Nutrisystem goodwill (see Note 12), which includes post-Closing adjustments related to final settlement, and $11.2 million of transaction costs directly related to the disposition of Nutrisystem.

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Financial Results Included in Income (Loss) from Discontinued Operations (Parenthetical) (Details) - Nutrisystem, Inc. - USD ($) $ in Thousands		Dec. 09, 2020	Dec. 31, 2020		Dec. 31, 2019	[3]	Dec. 08, 2020
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Interest expense	[2]		$ 36,798	[1]	$ 34,763
Impairment losses			90,200
Transaction costs directly related to disposition of Nutrition			$ 11,200
Long-term Debt
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Interest expense							$ 519,000
Long-term Debt | Credit Agreement
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Repayment of principal on the term loan		$ 519,000
[1]	Results include the period from January 1, 2020 through December 8, 2020.
[2]	The term loans under our Credit Agreement were originated with the purchase of Nutrisystem on March 8, 2019. Following the disposition of Nutrisystem, we repaid $519.0 million of principal on the Term Loans under the terms of the Credit Agreement. In conjunction with the partial debt prepayment, we wrote off a portion of the related deferred loan costs and original issue discount. We allocated interest expense to discontinued operations based on the interest expense incurred from March 8, 2019 through December 8, 2020 related to $519.0 million of term loan debt, using our historical interest rates.
[3]	Results include the period from March 8, 2019 (the date of acquisition) through December 31, 2019.

Discontinued Operations - Sum_4

Discontinued Operations - Summary of Depreciation, Amortization and Significant Operating and Investing Non-cash Items of the Discontinued Operations (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Discontinued Operation Alternative Cash Flow Information [Abstract]
Impairment of goodwill and intangible assets		$ 199,500	$ 377,100
Loss on sale of business		90,163		$ (1,304)
Depreciation and amortization		35,957	43,638
Loss on de-designation of cash flow hedges		14,336
Write-off of deferred loan costs and debt discount	[1]	8,946
Capital expenditures on discontinued operations		6,794	10,168
Share-based compensation on discontinued operations		4,351	13,230
Deferred income taxes		$ (54,561)	$ (68,488)
[1]	Reflected on the consolidated statement of cash flows in the line items “Amortization and write-off of deferred loan costs” and “Amortization and write-off of debt discount”.

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details)	Jan. 01, 2018USD ($)	Dec. 31, 2020USD ($)ProgramSegmentObligation	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Disaggregation Of Revenue [Line Items]
Number of programs | Program		4
Deferred revenue		$ 4,460,000	$ 4,336,000
Increase in deferred revenue	$ 3,200,000	$ 686,000	(1,198,000)
Number of reportable segments | Segment		1
Continuing Operations
Disaggregation Of Revenue [Line Items]
Number of programs | Program		3
Number of performance obligations | Obligation		1
Deferred revenue		$ 4,500,000	4,300,000
Revenue recognized		3,600,000
Increase in deferred revenue		$ 3,800,000
Period of billing in arrears once timing of services to customers is known		1 month
Number of days for customer to make payment after being invoiced		30 days
Capitalized costs		$ 800,000	500,000
Capitalized costs, amortization expense		$ 400,000	$ 100,000	$ 0
Number of reportable segments | Segment		1
Continuing Operations | SilverSneakers
Disaggregation Of Revenue [Line Items]
Revenues from PMPM fees percentage		54.00%	33.00%

Revenue Recognition - Summary o

Revenue Recognition - Summary of Revenue Disaggregated by Program (Details) - USD ($) $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2020

[1]

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Dec. 31, 2019

[2]

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

[3]

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Disaggregation Of Revenue [Line Items]

Revenue

$ 100,617

$ 95,481

$ 81,923

$ 159,692

$ 159,080

$ 159,979

$ 157,480

$ 156,527

$ 437,714

$ 633,066

$ 606,299

Other

Disaggregation Of Revenue [Line Items]

Revenue

6,800

Continuing Operations

Disaggregation Of Revenue [Line Items]

Revenue

437,714

633,066

606,299

Continuing Operations | SilverSneakers

Disaggregation Of Revenue [Line Items]

Revenue

313,575

492,778

487,559

Continuing Operations | Prime Fitness

Disaggregation Of Revenue [Line Items]

Revenue

95,015

120,949

101,391

Continuing Operations | WholeHealth Living

Disaggregation Of Revenue [Line Items]

Revenue

19,776

18,511

16,835

Continuing Operations | Other

Disaggregation Of Revenue [Line Items]

Revenue

[4]

$ 9,348

$ 828

$ 514

[1]

Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.

[2]

Income from continuing operations for the fourth quarter of 2019 includes acquisition, integration, and project costs totaling $4.3 million, which were primarily recorded to selling, general, and administrative expenses.

[3]

The impact of potentially dilutive securities for the three months ended March 31, 2019 was not considered because the impact on continuing operations would be anti-dilutive.

[4]

For the year ended December 31, 2020, other revenue in the table above includes $6.8 million from a well-being program with a large employer (which we do not expect to recur at this level) and $2.2 million from our Wisely Well program.

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Revenue Disaggregated by Program (Parenthetical) (Details) - USD ($) $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2020

[1]

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Dec. 31, 2019

[2]

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

[3]

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Disaggregation Of Revenue [Line Items]

Revenues

$ 100,617

$ 95,481

$ 81,923

$ 159,692

$ 159,080

$ 159,979

$ 157,480

$ 156,527

$ 437,714

$ 633,066

$ 606,299

Other

Disaggregation Of Revenue [Line Items]

Revenues

6,800

Well-Being Program

Disaggregation Of Revenue [Line Items]

Revenues

$ 2,200

[1]

Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.

[2]

Income from continuing operations for the fourth quarter of 2019 includes acquisition, integration, and project costs totaling $4.3 million, which were primarily recorded to selling, general, and administrative expenses.

[3]

The impact of potentially dilutive securities for the three months ended March 31, 2019 was not considered because the impact on continuing operations would be anti-dilutive.

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Total property and equipment at cost	$ 59,147	$ 56,108
Less: accumulated depreciation	(38,188)	(32,532)
Total property and equipment, net	20,959	23,576
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment at cost	7,963	7,659
Computer Equipment and Related Software
Property Plant And Equipment [Line Items]
Total property and equipment at cost	45,504	30,256
Furniture and Office Equipment
Property Plant And Equipment [Line Items]
Total property and equipment at cost	4,418	6,173
Capital Projects in Process
Property Plant And Equipment [Line Items]
Total property and equipment at cost	$ 1,262	$ 12,020

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Gross amount of goodwill of continuing operations	$ 517,000,000	$ 517,000,000
Accumulated impairment losses	182,400,000	182,400,000
Amortization	0	0	$ 0
Expected amortization expense, 2021	0
Expected amortization expense, 2022	0
Expected amortization expense, 2023	0
Expected amortization expense, 2024	0
Expected amortization expense, 2025	0
Expected amortization expense, thereafter	0
Tradename
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Intangible assets not subject to amortization	$ 29,000,000	$ 29,000,000

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Intangible Assets Subject to Amortization (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 10,192	$ 10,192
Accumulated Amortization	(10,192)	(10,192)
Acquired Technology
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,483	1,483
Accumulated Amortization	(1,483)	(1,483)
Distributor and Provider Networks
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	8,709	8,709
Accumulated Amortization	$ (8,709)	$ (8,709)

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2019$ / sharesshares	Dec. 31, 2020USD ($)Type$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Types of share based awards | Type		4
Share based awards, description		We currently have four types of share-based awards outstanding to our employees and directors: stock options, restricted stock units, performance-based stock units, and market stock units.
Post-combination expense recognized | $		$ 14,100	$ 18,800	$ 6,100
Number of shares reserved for future equity grants (in shares)		1,400,000
Total unrecognized compensation cost related to nonvested share-based compensation arrangements granted | $		$ 14,200
Weighted average period for recognition of unrecognized compensation cost		1 year 7 months 6 days
Stock options granted during period		220,000	0
Total intrinsic value of options exercised during period | $		$ 600	$ 600	3,900
Cash received from option exercised | $		1,025	989	1,910
Tax benefit realized from options exercised | $		$ 200
Total grant-date fair value of shares vested | $			$ 13,600	$ 23,500	$ 7,600
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards outstanding		0	127,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, vesting period		3 years
Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, expiration period		7 years
Stock Options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, expiration period		10 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards outstanding		1,241,000	393,000
Share based awards, granted		1,774,000
Share based awards, fair value | $ / shares		$ 11.17	$ 19.68	$ 38.12
Restricted Stock Units (RSUs) | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, vesting period		3 years
Restricted Stock Units (RSUs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, vesting period		4 years
Performance-Based Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards outstanding		86,000	407,000
Share based awards, granted		4,000		0
Share based awards, fair value | $ / shares		$ 21.49	$ 20.20
Performance-Based Stock Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, vesting period		2 years
Performance-Based Stock Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, vesting period		3 years
Market Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards outstanding		150,000
Share based awards, vesting period		3 years
Share based awards, granted		150,000	0	0
Share based awards, fair value | $ / shares		$ 18.84
Time-Vesting Restricted Stock Awards (Replacement Awards) | Employees | Nutrisystem
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, granted	258,000
Share based awards, fair value | $ / shares	$ 19.42
Time-Vesting Restricted Stock Units (Replacement Awards) | Employees | Nutrisystem
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based awards, granted	919,000
Share based awards, fair value | $ / shares	$ 19.42
Replacement Awards | Nutrisystem
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Post-combination expense recognized | $		$ 900	$ 9,900

Share-Based Compensation - Allo

Share-Based Compensation - Allocated Share-based Compensation Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs	$ 14.1	$ 18.8	$ 6.1
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs	2.7	2.2	2.3
Selling, General and Administrative Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs	6.2	3.4	3.8
Restructuring and Related Charges
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs	0.8
Continuing Operations
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs	9.7	5.6	6.1
Total income tax benefit recognized in continuing operations	2.5	1.4	$ 1.6
Discontinued Operations
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation costs	$ 4.4	$ 13.2

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Weighted Average Grant-date Fair Values of Options and Weighted Average Assumptions Used to Develop Fair Value Estimates (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant-date fair value of options per share	$ 8.20	$ 20.21
Assumptions:
Expected volatility	63.20%	56.20%
Expected term (in years)	6 years 2 months 12 days	6 years 8 months 12 days
Risk-free rate	0.70%	2.80%

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Shares [Roll Forward]
Outstanding, beginning of period (in shares)	319,000
Granted (in shares)	220,000	0
Exercised (in shares)	(81,000)
Forfeited (in shares)	(5,000)
Expired (in shares)	(31,000)
Outstanding, end of period (in shares)	422,000	319,000
Exercisable, end of period (in shares)	187,000
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 17.85
Granted (in dollars per share)	16.78
Exercised (in dollars per share)	12.67
Forfeited (in dollars per share)	39.55
Expired (in dollars per share)	20.76
Outstanding, end of period (in dollars per share)	17.83	$ 17.85
Exercisable, end of period (in dollars per share)	$ 17.54
Weighted-Average Remaining Contractual Term [Abstract]
Outstanding	5 years 2 months 12 days
Exercisable	3 years
Aggregate Intrinsic Value [Abstract]
Outstanding, end of period	$ 1,544
Exercisable, end of period	$ 927

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Restricted Stock Awards (Details) - Restricted Stock Awards	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Shares [Roll Forward]
Nonvested, beginning of period (in shares) | shares	127,000
Vested (in shares) | shares	(120,000)
Forfeited (in shares) | shares	(7,000)
Nonvested, end of period (in shares) | shares	0
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period (in dollars per share) | $ / shares	$ 19.42
Vested (in dollars per share) | $ / shares	19.42
Forfeited (in dollars per share) | $ / shares	$ 19.42
Nonvested, end of period (in dollars per share) | $ / shares

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Restricted Stock Units (Details) - Restricted Stock Units (RSUs) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Shares [Roll Forward]
Nonvested, beginning of period (in shares)	393
Granted (in shares)	1,774
Vested (in shares)	(692)
Forfeited (in shares)	(234)
Nonvested, end of period (in shares)	1,241	393
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period (in dollars per share)	$ 21.16
Granted (in dollars per share)	11.17	$ 19.68	$ 38.12
Vested (in dollars per share)	13.81
Forfeited (in dollars per share)	17.96
Nonvested, end of period (in dollars per share)	$ 11.58	$ 21.16

Share-Based Compensation - Su_5

Share-Based Compensation - Summary of Performance-Based Stock Units (Details) - Performance-Based Stock Units - $ / shares		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Shares [Roll Forward]
Nonvested, beginning of period (in shares)		407,000
Granted (in shares)		4,000		0
Shares adjustment for performance (in shares)	[1]	(74,000)
Vested (in shares)		(86,000)
Forfeited (in shares)		(165,000)
Nonvested, end of period (in shares)		86,000	407,000
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period (in dollars per share)		$ 20.29
Granted (in dollars per share)		21.49	$ 20.20
Shares adjustment for performance (in dollars per share)	[1]	20.26
Vested (in dollars per share)		20.42
Forfeited (in dollars per share)		20.26
Nonvested, end of period (in dollars per share)		$ 20.30	$ 20.29
[1]	Represents the number of shares at target for certain performance-based stock units that are no longer eligible to be earned as a result of actual performance being below the applicable performance targets. These awards are included in the nonvested balance at January 1, 2020 and the number of shares granted above.

Share-Based Compensation - Su_6

Share-Based Compensation - Summary of Market Stock Units (Details) - Market Stock Units - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Shares [Roll Forward]
Granted (in shares)	150,000	0	0
Nonvested, end of period (in shares)	150,000
Weighted-Average Grant Date Fair Value [Roll Forward]
Granted (in dollars per share)	$ 18.84
Nonvested, end of period (in dollars per share)	$ 18.84

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current taxes [Abstract]
Federal	$ 526	$ 3,051	$ 29
State	881	830	1,857
Deferred taxes [Abstract]
Federal	14,114	11,853	20,136
State	2,009	4,559	5,024
Total	$ 17,530	$ 20,293	$ 27,046

Income Taxes - Significant Comp

Income Taxes - Significant Components of Net Deferred Tax Asset and Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax asset [Abstract]
Accruals and reserves	$ 1,137	$ 498
Deferred compensation	604	191
Share-based payments	2,909	2,802
Lease liability	4,993	5,003
Section 163(j) interest limitation	370	5,647
Interest rate swap	5,964	4,147
Unrealized losses	3,720	0
Net operating loss carryforwards	10,608	7,200
Capital loss carryforwards	149,608	7,801
Deferred tax assets, gross	179,913	33,289
Valuation allowance	(152,295)	(13,147)
Total	27,618	20,142
Deferred tax liability [Abstract]
Property and equipment	(4,516)	(3,181)
Intangible assets	(14,868)	(14,651)
Right-of-use assets	(4,633)	(6,532)
Total	(24,017)	(24,364)
Net long-term deferred tax asset	$ 3,601
Net long-term deferred tax liability		$ (4,222)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance on deferred tax assets related to net operating loss carryforwards	$ 139,100
Increase in income tax expense		$ 2,700
Capital loss carryforwards	149,608	7,801
Valuation allowance	152,295	13,147
Tax effect related to interest rate swap agreements	5,964	4,147
Unrecognized tax benefits	1,100	1,061	$ 0
Unrecognized tax benefits that affect our effective tax rate	0
Indefinite Carryforward
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	8,000
Capital Loss Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards	$ 598,400
Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Open tax year	2017
Earliest Tax Year | Capital Loss Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards, expiration dates	Dec. 31, 2021
Latest Tax Year | Capital Loss Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards, expiration dates	Dec. 31, 2025
TPHS and Nutrisystem
Operating Loss Carryforwards [Line Items]
Capital loss carryforwards	$ 149,600
International
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards valuation allowance	2,400
Operating loss carryforwards	8,200
State
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance on deferred tax assets related to net operating loss carryforwards	(2,700)	1,800
Reduction in deferred tax asset related to income tax credits		$ 900
Operating loss carry forwards valuation allowance	300
Operating loss carryforwards	$ 159,000
State | Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates	Dec. 31, 2021
State | Latest Tax Year
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates	Dec. 31, 2036

Income Taxes - Effective Income

Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Difference Between Income Tax Expense Computed Using Statutory Federal Income Tax Rate And Effective Rate [Abstract]
Statutory federal income tax	$ 15,624	$ 13,757	$ 26,239
State income taxes, less federal income tax benefit	3,607	3,048	6,261
Permanent items	1,131	306	1,496
Change in valuation allowance	(2,659)	2,509	(1,005)
Share-based compensation	426	210	(6,378)
State income tax credits		954	677
Change in uncertain tax position liability			(644)
Prior year tax adjustments	(592)	(464)	(590)
Net impact of foreign operations	(3)	9	(990)
Other	(10)	(18)
Total	$ 17,530	$ 20,293	$ 27,046

Income Taxes - Uncertain Tax Po

Income Taxes - Uncertain Tax Positions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Changes in Unrecognized Tax Benefits [Roll Forward]
Balance, beginning of period	$ 1,061	$ 0
Increases related to acquisition of Nutrisystem		1,006
Increases related to current year tax positions		8
Increases related to prior year tax positions	84	66
Decreases due to lapse of statute of limitations	(20)	(19)
Balance, end of period	1,100	$ 1,061
Decreases related to Nutrisystem divestiture	$ (1,125)

Leases - Additional Information

Leases - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020Agreement
Lessee Lease Description [Line Items]
Number of sublease agreements	2
Minimum
Lessee Lease Description [Line Items]
Remaining lease terms	1 month
Maximum
Lessee Lease Description [Line Items]
Remaining lease terms	45 months

Leases - Schedule of Right-of-U

Leases - Schedule of Right-of-Use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Right-of-use assets:
Operating	$ 17,145	$ 23,895
Finance	994	1,680
Total leased assets	18,139	25,575
Current
Operating	$ 7,408	$ 7,274
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	tvty:CurrentLeaseLiabilities	tvty:CurrentLeaseLiabilities
Finance	$ 644	$ 624
Non-current
Operating	$ 11,097	$ 18,505
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	tvty:NoncurrentLeaseLiabilities	tvty:NoncurrentLeaseLiabilities
Finance	$ 397	$ 1,080
Total lease liabilities	$ 19,546	$ 27,483

Leases - Schedule of Components

Leases - Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Amortization of leased assets	$ 686	$ 298
Interest of lease liabilities	86	51
Operating lease cost	7,872	8,817
Total lease cost before subleases	8,644	9,166
Sublease income	(5,452)	(5,479)
Total lease cost, net	$ 3,192	$ 3,687

Leases - Schedule of Weighted A

Leases - Schedule of Weighted Average Remaining Term and Discount Rates (Details)	Dec. 31, 2020
Weighted Average Remaining Lease Term (years)
Operating leases, Weighted average remaining lease term (years)	2 years 7 months 6 days
Finance leases, Weighted average remaining lease term (years)	1 year 7 months 6 days
Weighted Average Discount Rate
Operating leases, Weighted average discount rate	4.80%
Finance leases, Weighted average discount rate	5.90%

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2020USD ($)
Operating Leases Lease Payments
2021	$ 8,115
2022	7,957
2023	2,518
2024	1,083
Total lease payments	19,673
Less: interest	(1,168)
Present value of lease liabilities	18,505
Operating Leases Sublease Receipts
2021	(5,699)
2022	(5,732)
2023	(957)
Total Operating Leases Sublease Receipts	(12,388)
Operating Leases Net
2021	2,416
2022	2,225
2023	1,561
2024	1,083
Total operating lease payments Net	7,285
Financing Leases
2021	686
2022	403
Total lease payments	1,089
Less: interest	(48)
Present value of lease liabilities	$ 1,041

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flow attributable to operating leases		$ (3,492)	$ (4,626)
Operating cash flow attributable to finance leases		(86)	(51)
Financing cash flow attributable to finance leases		$ (622)	(274)
Supplemental noncash information:
Right-of-use assets obtained in exchange for operating lease liabilities	[1]		31,538
Right-of-use assets obtained in exchange for finance lease liabilities	[2]		$ 1,978
[1]	No new operating leases were entered into during the year ended December 31, 2019.  Amount shown is due to the adoption of ASC 842 and one lease modification that resulted in a noncash remeasurement of the related right-of-use asset and operating lease liability. Amount shown reflects balance as of January 1, 2019, adjusted for lease modification.
[2]	Amount shown is due to the adoption of ASC 842 and one new finance lease for $1.8 million entered into during the year ended December 31, 2019. In addition to such lease, amount shown reflects balance as of January 1, 2019.

Leases - Schedule of Suppleme_2

Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Parenthetical) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Lessee Lease Description [Line Items]
Finance lease recognized due to adoption of accounting standard	$ 1,978	[1]
Adoption of ASC 842 | Revision of Prior Period, Accounting Standards Update, Adjustment
Lessee Lease Description [Line Items]
Finance lease recognized due to adoption of accounting standard	$ 1,800
[1]	Amount shown is due to the adoption of ASC 842 and one new finance lease for $1.8 million entered into during the year ended December 31, 2019. In addition to such lease, amount shown reflects balance as of January 1, 2019.

Debt - Summary of Debt, Net of

Debt - Summary of Debt, Net of Unamortized Deferred Loan Costs And Original Issue Discount (Details) - USD ($) $ in Thousands		Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount		$ 496,275	$ 1,094,850
Less: deferred loan costs and original issue discount		(29,569)	(46,723)
Total debt		466,706	1,048,127
Less: current portion	[1]	(7,456)
Total long-term debt		459,250	1,048,127
Term Loan A
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount		124,035	288,750
Term Loan B
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount		$ 372,240	786,250
Revolving Credit Facility
Debt Instrument [Line Items]
Debt, net of unamortized original issue discount			$ 19,850
[1]	Represents additional term loan principal due upon final settlement of the sale of Nutrisystem based on the estimated post-Closing adjustments.

Debt - Credit Facility - Additi

Debt - Credit Facility - Additional Information (Details)	Mar. 08, 2019USD ($)	Dec. 31, 2020USD ($)	May 31, 2019Agreement	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)
Line Of Credit Facility [Line Items]
Outstanding debt		$ 466,706,000		$ 466,706,000	$ 1,048,127,000	$ 466,706,000	$ 1,048,127,000	$ 466,706,000
Interest Rate Swap Agreements
Line Of Credit Facility [Line Items]
Number of agreements held for maturity | Agreement			8
Derivative maturity month and year			2024-05
Interest Rate Swap Agreements | LIBOR
Line Of Credit Facility [Line Items]
Derivative, fixed interest rate			2.20%
Eight Interest Rate Swaps
Line Of Credit Facility [Line Items]
Derivative, notional amount		700,000,000		700,000,000		700,000,000		700,000,000
Eight Interest Rate Swaps | Hedges
Line Of Credit Facility [Line Items]
Derivative, notional amount		388,900,000		$ 388,900,000		388,900,000		388,900,000
Description of interest rate swaps on derivatives				we concluded that five of the eight interest rate swaps no longer qualified for hedge accounting treatment, and we de-designated these derivatives.
Revolving Credit Facility
Line Of Credit Facility [Line Items]
Available borrowing capacity		124,500,000		$ 124,500,000		$ 124,500,000		124,500,000
Credit Agreement
Line Of Credit Facility [Line Items]
Initiation date						Mar. 8, 2019
Outstanding debt		466,700,000		$ 466,700,000		$ 466,700,000		$ 466,700,000
Net leverage ratio for next twelve month						5.75
Net leverage ratio in year two						5.25
Net leverage ratio thereafter						4.75
Net leverage ratio one						2.36
Debt instrument, prepayments description						We are required to make prepayments on the Term Loans equal to our excess cash flow for a given fiscal year multiplied by the following excess cash flow percentages based on our Net Leverage Ratio (as defined in the Credit Agreement) on the last day of such fiscal year: (a) 75% if the Net Leverage Ratio is greater than 3.75:1, (b) 50% if the Net Leverage Ratio is equal to or less than 3.75:1 but greater than 3.25:1 (c) 25% if the Net Leverage Ratio is equal to or less than 3.25:1 but greater than 2.75:1, and (d) 0% if the Net Leverage Ratio is equal to or less than 2.75:1.
Term loan paydown amount						$ 519,000,000
Commitment fees						$ 500,000	$ 500,000
Credit Agreement | Federal Funds Rate
Line Of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
Credit Agreement | One-Month LIBOR
Line Of Credit Facility [Line Items]
Basis spread on variable rate	1.00%
Credit Agreement | Net Leverage Ratio Greater Than 3.75:1
Line Of Credit Facility [Line Items]
Excess cash flow percentage						75.00%
Net leverage ratio						375.00%
Credit Agreement | Net Leverage Ratio Equal To or Less Than 3.75:1 but Greater Than 3.25:1
Line Of Credit Facility [Line Items]
Excess cash flow percentage						50.00%
Net leverage ratio						325.00%
Credit Agreement | Net Leverage Ratio Equal To or Less Than 3.25:1 but Greater Than 2.75:1
Line Of Credit Facility [Line Items]
Excess cash flow percentage						25.00%
Net leverage ratio						275.00%
Credit Agreement | Net Leverage Ratio Equal To or Less Than 2.75:1
Line Of Credit Facility [Line Items]
Excess cash flow percentage						0.00%
Credit Agreement | Nutrisystem, Inc.
Line Of Credit Facility [Line Items]
Payments on term loans		$ 519,000,000
Credit Agreement | Minimum
Line Of Credit Facility [Line Items]
Unused commitment fee percentage	0.25%
Credit Agreement | Minimum | LIBOR
Line Of Credit Facility [Line Items]
Variable rate basis	0.00%
Credit Agreement | Maximum
Line Of Credit Facility [Line Items]
Unused commitment fee percentage	0.50%
Credit Agreement | Revolving Credit Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 125,000,000
Maturity date						Mar. 8, 2024
Credit Agreement | Revolving Credit Facility | Minimum | LIBOR
Line Of Credit Facility [Line Items]
Margin rate	3.75%
Credit Agreement | Revolving Credit Facility | Minimum | Base Rate
Line Of Credit Facility [Line Items]
Margin rate	2.75%
Credit Agreement | Revolving Credit Facility | Maximum | LIBOR
Line Of Credit Facility [Line Items]
Margin rate	4.25%
Credit Agreement | Revolving Credit Facility | Maximum | Base Rate
Line Of Credit Facility [Line Items]
Margin rate	3.25%
Credit Agreement | Swingline Sub Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 35,000,000
Maturity date						Mar. 8, 2024
Credit Agreement | Letters of Credit Sub Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	50,000,000
Credit Agreement | Term Loan Facility A
Line Of Credit Facility [Line Items]
Debt instrument, face amount	$ 350,000,000
Periodic principal payment as percentage of aggregate principal amount	2.50%
Maturity date						Mar. 8, 2024
Effective interest rates		6.64%		6.64%	5.47%	6.64%	5.47%	6.64%
Credit Agreement | Term Loan Facility A | LIBOR
Line Of Credit Facility [Line Items]
Margin rate	4.25%
Credit Agreement | Term Loan Facility A | Base Rate
Line Of Credit Facility [Line Items]
Margin rate	3.25%
Credit Agreement | Term Loan Facility B
Line Of Credit Facility [Line Items]
Debt instrument, face amount	$ 830,000,000
Periodic principal payment as percentage of aggregate principal amount	0.75%
Maturity date						Mar. 8, 2026
Effective interest rates		7.08%		7.08%	6.27%	7.08%	6.27%	7.08%
Credit Agreement | Term Loan Facility B | LIBOR
Line Of Credit Facility [Line Items]
Margin rate	5.25%
Credit Agreement | Term Loan Facility B | Base Rate
Line Of Credit Facility [Line Items]
Margin rate	4.25%
Credit Agreement | Uncommitted Incremental Accordion Facility | Minimum
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 125,000,000
Percentage of consolidated EBITDA requirement	50.00%
Credit Agreement | Term Loans
Line Of Credit Facility [Line Items]
Payments on term loans								$ 164,700,000
Maturity date					Dec. 31, 2021

Debt - Minimum Annual Principal

Debt - Minimum Annual Principal Payments and Repayments of the Revolving Advances (Details) - USD ($) $ in Thousands		Dec. 31, 2020	Dec. 31, 2019
Minimum annual principal payments and repayments of the revolving advances [Abstract]
2021	[1]	$ 7,456
2022		59,900
2023		59,900
2024		77,071
2025		24,900
2026 and thereafter		267,048
Total		$ 496,275	$ 1,094,850
[1]	The total term loan principal due during 2021 reflects $7.5 million of additional debt repayment required upon estimated final settlement of the Nutrisystem sale.

Debt - Minimum Annual Princip_2

Debt - Minimum Annual Principal Payments and Repayments of the Revolving Advances (Parenthetical) (Details) $ in Millions	Dec. 31, 2020USD ($)
Nutrisystem, Inc.
Line Of Credit Facility [Line Items]
Additional debt repayment upon estimated final settlement	$ 7.5

Commitments and Contingencies -

Commitments and Contingencies - Additional Information - (Details)	Nov. 06, 2017Lawsuit$ / shares	Dec. 31, 2020$ / shares	Dec. 31, 2019$ / shares
Commitments And Contingencies Disclosure [Abstract]
Common stock, par value (in dollars per share) | $ / shares	$ 0.001	$ 0.001	$ 0.001
Number of lawsuits filed	4
Number of lawsuits dismissed	1
Number of lawsuits dismissed and plaintiffs appealed	2
Number of lawsuits actively contested	1

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Oct. 18, 2020	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020		Dec. 31, 2019		Dec. 31, 2018	Dec. 09, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total impairment loss						$ 199,500,000		$ 377,100,000
Proceeds from sale of business						558,067,000				$ 1,416,000
Outstanding debt		$ 466,706,000				466,706,000		1,048,127,000
Term Loans
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt instrument net fair value		463,200,000				463,200,000
Outstanding debt		466,700,000				466,700,000
Revolving Credit Facility
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Line of credit		0				0
Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash and cash equivalents		100,400,000				100,400,000
Nutrisystem, Inc.
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total impairment loss				$ 199,500,000		199,500,000	[1]	377,100,000	[2]
Goodwill impairment loss						90,200,000
Proceeds from sale of business						$ 550,500,000
Customary indebtedness and cash adjustments											$ 558,900,000
Carrying value of disposal group								$ 1,088,458,000			585,700,000
Estimated gross proceeds excluding transaction costs											$ 561,700,000
Nutrisystem, Inc. | Forecast
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Proceeds from sale of business					$ 2,800,000
Nutrition Business Unit
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Proceeds from sale of business	$ 575,000,000
Continuing Operations
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Goodwill impairment loss				0
Discontinued Operations | Nutrition
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Goodwill impairment loss		$ 24,000,000	$ 66,200,000
SilverSneakers | Continuing Operations | Tradename
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Impairment loss of intangibles				$ 0
[1]	Results include the period from January 1, 2020 through December 8, 2020.
[2]	Results include the period from March 8, 2019 (the date of acquisition) through December 31, 2019.

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Interest Rate Swap Agreements - Fair Value, Measurements, Recurring - Level 2 - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Derivatives Designated as Effective Hedging Instruments
Liabilities:
Liabilities measured at fair value	$ 20,377	$ 16,238
Derivatives Not Designated as Hedging Instruments
Liabilities:
Liabilities measured at fair value	$ 16,260

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Details) - Interest Rate Swap Agreements	1 Months Ended		3 Months Ended	12 Months Ended
	Oct. 31, 2020USD ($)	May 31, 2019Agreement	Dec. 31, 2020USD ($)Agreement	Dec. 31, 2020USD ($)Agreement
Derivative [Line Items]
Number of interest rate swap agreements not qualified for hedge accounting treatment | Agreement				5
Number of interest rate swap agreements maintains hedging relationship | Agreement				3
Derivatives Designated as Hedging Instruments | Cash Flow Hedging
Derivative [Line Items]
Number of amortizing interest rate swap agreements | Agreement		8
Derivative maturity month and year		2024-05
Derivative, fixed interest rate		2.20%
Derivative, notional amount			$ 388,900,000	$ 388,900,000
Derivative amount reclassify from accumulated OCI to interest expense within next 12 months			$ 8,800,000	8,800,000
Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Number of de-designated amortizing interest rate swap agreements | Agreement			5
Amount frozen that are previously deferred	$ 3,200,000
Derivative, notional amount			$ 311,100,000	$ 311,100,000
Recognized pre-tax loss on derivatives in discontinued operations			$ 14,300,000
Floor interest rate of swaps			0.00%	0.00%

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Schedule of Estimated Gross Fair Values of Derivative Instruments and Their Classification on Consolidated Balance Sheet (Details) - Interest Rate Swap Agreements - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Derivatives Designated as Effective Hedging Instruments | Cash Flow Hedging
Liabilities:
Derivative liabilities	$ 20,377	$ 16,238
Derivatives Not Designated as Hedging Instruments
Liabilities:
Derivative liabilities	16,260
Current Portion of Long-term Liabilities | Derivatives Designated as Effective Hedging Instruments | Cash Flow Hedging
Liabilities:
Current portion of long-term liabilities	8,205	4,947
Current Portion of Long-term Liabilities | Derivatives Not Designated as Hedging Instruments
Liabilities:
Current portion of long-term liabilities	6,548
Other Long-term Liabilities | Derivatives Designated as Effective Hedging Instruments | Cash Flow Hedging
Liabilities:
Other long-term liabilities	12,172	$ 11,291
Other Long-term Liabilities | Derivatives Not Designated as Hedging Instruments
Liabilities:
Other long-term liabilities	$ 9,712

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Schedule of Effect of Cash Flow Hedge Accounting on Accumulated OCI (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments Gain Loss [Line Items]
Total other comprehensive loss, gross of tax	$ (5,298)	$ (12,091)
Interest Rate Swap Agreements | Derivatives Designated as Effective Hedging Instruments | Cash Flow Hedging
Derivative Instruments Gain Loss [Line Items]
Loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect	33,247	16,930
Interest Rate Swap Agreements | Derivatives Not Designated as Hedging Instruments
Derivative Instruments Gain Loss [Line Items]
Loss related to de-designation of ineffective portion of derivatives, gross of tax effect	(14,336)
Total other comprehensive loss, gross of tax	7,116	16,238
Interest Rate Swap Agreements | Interest Expense | Derivatives Designated as Effective Hedging Instruments | Cash Flow Hedging
Derivative Instruments Gain Loss [Line Items]
Loss related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect	(11,556)	$ (692)
Interest Rate Swap Agreements | Interest Expense | Derivatives Not Designated as Hedging Instruments
Derivative Instruments Gain Loss [Line Items]
Previously deferred loss reclassified from accumulated OCI to interest expense, gross of tax effect	$ (239)

Derivative Instruments and He_6

Derivative Instruments and Hedging Activities - Schedule of Impact of Derivatives Not Designated as Hedges on Consolidated Statement of Operations (Details) - Derivatives Not Designated as Hedging Instruments - Interest Rate Swap $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Derivative Instruments Gain Loss [Line Items]
Impact of derivative instruments not designated as hedges	$ (14,801)
Income From Discontinued Operations, Net of Income Tax
Derivative Instruments Gain Loss [Line Items]
Loss related to de-designation of ineffective portion of derivatives, gross of tax effect	(14,336)
Selling, General and Administrative Expenses
Derivative Instruments Gain Loss [Line Items]
Net loss related to ineffective portion of derivatives, gross of tax effect	(226)
Interest Expense
Derivative Instruments Gain Loss [Line Items]
Previously deferred loss reclassified from accumulated OCI to interest expense, gross of tax effect	$ (239)

Restructuring and Related Cha_3

Restructuring and Related Charges - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Restructuring Cost And Reserve [Line Items]
Restructuring and related charges	$ 4,358,000	$ 1,881,000	$ 124,000
Non-cash restructuring charges related to share-based compensation	800,000
Continuing Operations
Restructuring Cost And Reserve [Line Items]
Restructuring and related charges	3,618,000
2019 Restructuring Plan | Continuing Operations
Restructuring Cost And Reserve [Line Items]
Restructuring and related charges	475,000	$ 1,900,000
Restructuring charges incurred	2,400
2020 COVID Restructuring Plan | Continuing Operations
Restructuring Cost And Reserve [Line Items]
Restructuring and related charges	816,000
Restructuring charges incurred	800,000
Total annualized savings	6,000,000
2020 Restructuring Plan | Continuing Operations
Restructuring Cost And Reserve [Line Items]
Restructuring and related charges	2,327,000
Restructuring charges incurred	3,100,000
Total annualized savings	$ 6,700,000

Restructuring and Related Cha_4

Restructuring and Related Charges - Schedule of Accrued Restructuring and Related Charges Activity (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Restructuring Cost And Reserve [Line Items]
Restructuring and related charges	$ 4,358	$ 1,881	$ 124
Continuing Operations
Restructuring Cost And Reserve [Line Items]
Accrued restructuring and related charges liability	242
Restructuring and related charges	3,618
Payments	(1,936)
Accrued restructuring and related charges liability	1,924	242
Continuing Operations | 2019 Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Accrued restructuring and related charges liability	242
Restructuring and related charges	475	1,900
Payments	(606)
Accrued restructuring and related charges liability	111	$ 242
Continuing Operations | 2020 COVID Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Restructuring and related charges	816
Payments	(816)
Continuing Operations | 2020 Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Restructuring and related charges	2,327
Payments	(514)
Accrued restructuring and related charges liability	$ 1,813

Earnings (Loss) Per Share - Rec

Earnings (Loss) Per Share - Reconciliation of the Numerator and Denominator of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended																12 Months Ended
	Dec. 31, 2020	[1]	Sep. 30, 2020		Jun. 30, 2020		Mar. 31, 2020		Dec. 31, 2019	[2]	Sep. 30, 2019		Jun. 30, 2019		Mar. 31, 2019	[3]	Dec. 31, 2020		Dec. 31, 2019		Dec. 31, 2018
Numerator [Abstract]
Net income (loss) from discontinued operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share	$ (26,260)		$ (59,168)		$ 11,309		$ (206,381)		$ (340,943)		$ (2,769)		$ 7,299		$ 4,375		$ (280,500)		$ (332,038)		$ 901
Net income (loss)	(11,618)		(42,418)		28,511		(198,106)		(323,090)		13,919		18,136		4,214		(223,631)		(286,821)		98,803
Income from continuing operations attributable to Tivity Health, Inc. - numerator for earnings (loss) per share	$ 14,642		$ 16,750		$ 17,202		$ 8,275		$ 17,853		$ 16,688		$ 10,837		$ (161)		$ 56,869		$ 45,217		$ 97,902
Denominator [Abstract]
Shares used for basic income (loss) per share																	48,746		46,509		40,078
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Shares used for diluted income (loss) per share																	49,217		47,103		43,073
Earnings (loss) per share attributable to Tivity Health, Inc. - basic [Abstract]
Continuing operations (in dollars per share)	$ 0.30	[4]	$ 0.34	[4]	$ 0.35	[4]	$ 0.17	[4]	$ 0.37	[4]	$ 0.35	[4]	$ 0.23	[4]			$ 1.17		$ 0.97		$ 2.44
Discontinued operations (in dollars per share)	(0.54)	[4]	(1.21)	[4]	0.23	[4]	(4.25)	[4]	(7.06)	[4]	(0.06)	[4]	0.15	[4]	$ 0.10	[4]	(5.75)		(7.14)		0.02
Net income (loss)	(0.24)	[4]	(0.87)	[4]	0.59	[4]	(4.08)	[4]	(6.69)	[4]	0.29	[4]	0.38	[4]	0.10	[4]	(4.59)	[5]	(6.17)	[5]	2.47	[5]
Earnings (loss) per share attributable to Tivity Health, Inc. - diluted [Abstract]
Continuing operations (in dollars per share)	0.29	[4]	0.34	[4]	0.35	[4]	0.17	[4]	0.37	[4]	0.34	[4]	0.22	[4]			1.16		0.96		2.27
Discontinued operations (in dollars per share)	(0.53)	[4]	(1.20)	[4]	0.23	[4]	(4.22)	[4]	(6.97)	[4]	(0.06)	[4]	0.15	[4]	0.10	[4]	(5.70)		(7.05)		0.02
Net income (loss)	$ (0.23)	[4]	$ (0.86)	[4]	$ 0.58	[4]	$ (4.05)	[4]	$ (6.61)	[4]	$ 0.29	[4]	$ 0.37	[4]	$ 0.10	[4]	$ (4.54)		$ (6.09)		$ 2.29
Non-Qualified Stock Options
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																	29		90		264
Restricted Stock Units (RSUs)
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																	412		489		299
Warrants Related to Cash Convertible Notes
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																					2,013
Market Stock Units
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																	1				419
Performance-Based Stock Units
Effect of dilutive stock options and restricted stock units outstanding [Abstract]
Effect of dilutive stock options and restricted stock units outstanding (in shares)																	29		15
Non-Qualified Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)																	186		70		56
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)																	242		192		36
Restricted Stock Awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)																	26		102
Performance-Based Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive (in shares)																	24
[1]	Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.
[2]	Income from continuing operations for the fourth quarter of 2019 includes acquisition, integration, and project costs totaling $4.3 million, which were primarily recorded to selling, general, and administrative expenses.
[3]	The impact of potentially dilutive securities for the three months ended March 31, 2019 was not considered because the impact on continuing operations would be anti-dilutive.
[4]	We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share.
[5]	Figures may not add due to rounding.

Accumulated OCI - Changes in Ac

Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Changes in accumulated OCI, net of tax [Roll Forward]
Amounts reclassified from accumulated OCI, net of tax	$ 19,458	$ 515
Interest Rate Swap
Changes in accumulated OCI, net of tax [Roll Forward]
Balance	(12,091)
Other comprehensive income (loss) before reclassifications, net	(24,756)	(12,606)
Amounts reclassified from accumulated OCI, net of tax	19,458	515
Balance	$ (17,389)	$ (12,091)

Accumulated OCI - Changes in _2

Accumulated OCI - Changes in Accumulated OCI, Net of Tax (Parenthetical) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Other comprehensive income before reclassifications, tax	$ 8,491	$ 4,324
Amounts reclassified from accumulated OCI, tax	$ 6,674	$ 177

Accumulated OCI - Schedule of R

Accumulated OCI - Schedule of Reclassifications Out of Accumulated OCI (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Interest expense	$ 43,477	$ 41,803	$ 8,733
Income tax	(17,530)	(20,293)	(27,046)
Income from discontinued operations, net of income tax	(280,500)	(332,038)	$ 901
Total amounts reclassified from accumulated OCI	19,458	515
Interest Rate Swap Agreements
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Total amounts reclassified from accumulated OCI	19,458	515
Reclassifications Out of Accumulate OCI
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Income tax	(3,012)	(177)
Income from discontinued operations, net of income tax	10,675
Reclassifications Out of Accumulate OCI | Interest Rate Swap Agreements
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Interest expense	$ 11,795	$ 692

Segment Disclosures and Conce_2

Segment Disclosures and Concentrations of Risk - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020SegmentCustomer	Dec. 31, 2019Customer
Revenue, Major Customer [Line Items]
Number of reportable segments | Segment	1
Percentage of long-lived assets and revenue from external customers in united states	100.00%	100.00%
Customer Concentration Risk | Revenues
Revenue, Major Customer [Line Items]
Number of largest individual customers | Customer	3	3
Number of additional individual customers | Customer	0	0
Customer Concentration Risk | Revenues | Minimum
Revenue, Major Customer [Line Items]
Percentage of concentration risk	10.00%	10.00%
Customer Concentration Risk | Revenues | Customer One
Revenue, Major Customer [Line Items]
Percentage of concentration risk	18.00%	23.00%
Customer Concentration Risk | Revenues | Customer Two
Revenue, Major Customer [Line Items]
Percentage of concentration risk	11.00%	11.00%
Customer Concentration Risk | Revenues | Customer Three
Revenue, Major Customer [Line Items]
Percentage of concentration risk	10.00%	11.00%
Customer Concentration Risk | Accounts Receivable, Net
Revenue, Major Customer [Line Items]
Number of largest individual customers | Customer	2	3
Customer Concentration Risk | Accounts Receivable, Net | Minimum
Revenue, Major Customer [Line Items]
Percentage of concentration risk	10.00%	10.00%
Customer Concentration Risk | Accounts Receivable, Net | Customer One
Revenue, Major Customer [Line Items]
Percentage of concentration risk	26.00%	36.00%
Customer Concentration Risk | Accounts Receivable, Net | Customer Two
Revenue, Major Customer [Line Items]
Percentage of concentration risk	33.00%	19.00%
Customer Concentration Risk | Accounts Receivable, Net | Customer Three
Revenue, Major Customer [Line Items]
Percentage of concentration risk		11.00%
Healthcare
Revenue, Major Customer [Line Items]
Number of operating segments | Segment	1
Number of reportable segments | Segment	1

Quarterly Financial Informati_3

Quarterly Financial Information (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended																12 Months Ended
	Dec. 31, 2020	[1]	Sep. 30, 2020		Jun. 30, 2020		Mar. 31, 2020		Dec. 31, 2019	[2]	Sep. 30, 2019		Jun. 30, 2019		Mar. 31, 2019	[3]	Dec. 31, 2020		Dec. 31, 2019		Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 100,617		$ 95,481		$ 81,923		$ 159,692		$ 159,080		$ 159,979		$ 157,480		$ 156,527		$ 437,714		$ 633,066		$ 606,299
Gross margin	44,168		45,382		45,879		42,713		47,271		46,852		44,903		42,303
Income before income taxes	15,793		23,236		23,959		11,411		23,417		22,864		15,743		3,486		74,399		65,510		124,948
Income from continuing operations	14,642		16,750		17,202		8,275		17,853		16,688		10,837		(161)		56,869		45,217		97,902
Income (loss) from discontinued operations, net of income tax	(26,260)		(59,168)		11,309		(206,381)		(340,943)		(2,769)		7,299		4,375		(280,500)		(332,038)		901
Net income (loss)	$ (11,618)		$ (42,418)		$ 28,511		$ (198,106)		$ (323,090)		$ 13,919		$ 18,136		$ 4,214		$ (223,631)		$ (286,821)		$ 98,803
Earnings (loss) per share - basic:
Continuing operations	$ 0.30	[4]	$ 0.34	[4]	$ 0.35	[4]	$ 0.17	[4]	$ 0.37	[4]	$ 0.35	[4]	$ 0.23	[4]			$ 1.17		$ 0.97		$ 2.44
Discontinued operations	(0.54)	[4]	(1.21)	[4]	0.23	[4]	(4.25)	[4]	(7.06)	[4]	(0.06)	[4]	0.15	[4]	$ 0.10	[4]	(5.75)		(7.14)		0.02
Net income (loss)	(0.24)	[4]	(0.87)	[4]	0.59	[4]	(4.08)	[4]	(6.69)	[4]	0.29	[4]	0.38	[4]	0.10	[4]	(4.59)	[5]	(6.17)	[5]	2.47	[5]
Earnings (loss) per share – diluted:
Continuing operations	0.29	[4]	0.34	[4]	0.35	[4]	0.17	[4]	0.37	[4]	0.34	[4]	0.22	[4]			1.16		0.96		2.27
Discontinued operations	(0.53)	[4]	(1.20)	[4]	0.23	[4]	(4.22)	[4]	(6.97)	[4]	(0.06)	[4]	0.15	[4]	0.10	[4]	(5.70)		(7.05)		0.02
Net income (loss)	$ (0.23)	[4]	$ (0.86)	[4]	$ 0.58	[4]	$ (4.05)	[4]	$ (6.61)	[4]	$ 0.29	[4]	$ 0.37	[4]	$ 0.10	[4]	$ (4.54)		$ (6.09)		$ 2.29
[1]	Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.
[2]	Income from continuing operations for the fourth quarter of 2019 includes acquisition, integration, and project costs totaling $4.3 million, which were primarily recorded to selling, general, and administrative expenses.
[3]	The impact of potentially dilutive securities for the three months ended March 31, 2019 was not considered because the impact on continuing operations would be anti-dilutive.
[4]	We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share.
[5]	Figures may not add due to rounding.

Quarterly Financial Informati_4

Quarterly Financial Information (unaudited) (Parenthetical) (Details) - USD ($) $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2020

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

[3]

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Income from continuing operations

$ 14,642

[1]

$ 16,750

$ 17,202

$ 8,275

$ 17,853

[2]

$ 16,688

$ 10,837

$ (161)

$ 56,869

$ 45,217

$ 97,902

Selling, General and Administrative Expenses

Acquisition and integration costs

600

Business acquisition, integration and project Costs

$ 4,300

$ 4,300

Strategic Project Costs | Selling, General and Administrative Expenses

Income from continuing operations

2,300

CEO Transition Costs | Selling, General and Administrative Expenses

Income from continuing operations

$ 1,000

[1]

Income from continuing operations for the fourth quarter of 2020 includes strategic project costs, CEO transition costs, and acquisition and integration costs of $2.3 million, $1.0 million, and $0.6 million, respectively, each of which were primarily recorded to selling, general, and administrative expenses.

[2]

Income from continuing operations for the fourth quarter of 2019 includes acquisition, integration, and project costs totaling $4.3 million, which were primarily recorded to selling, general, and administrative expenses.

[3]

The impact of potentially dilutive securities for the three months ended March 31, 2019 was not considered because the impact on continuing operations would be anti-dilutive.